Poster session I Friday June 16

Education sessions | Lunch debates | Opening Ceremony | ESH-EHA Joint Symposium | Poster Session I


Poster presentation during Poster-walks from 17.45 - 19.00 hours Poster area (behind Exhibition)

POSTER SESSION I

17.45 - 19.00 hours, Poster area (behind Exhibition)

IRON DISEASES

0001 5 YEARS OF COMBINED CHELATION THERAPY: A RADICAL CHANGE IN BETA-THALASSAEMIA MAJOR PATIENT CONDITION
K.F. Farmaki (General Hospital of Corinth, Corinth, Greece
 
0002 PEARSON SYNDROME IN AN INFANT HETEROZYGOUS FOR C282Y ALLELE OF HFE GENE
E. Roilides, K. Kefala-Agoropoulou, E. Roilides, E. Karatza, A. Lazaridou, E. Farmaki, P. Augoustides-Savvopoulou, C. Tsantali, J. Tsiouris (Aristotle University, Thessaloniki, Greece
 
0003 CHELATION THERAPY WITH DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSION-DEPENDENT SICKLE-CELL DISEASE: A COST-EFFECTIVENESS ANALYSIS FROM THE US PERSPECTIVE
E Delea, O. Sofrygin, J.F. Baladi, S.K. Thomas, T.D. Coates (Policy Analysis Inc. (PAI), Brookline, Ma, USA
 
0004 MANNOSE BINDING LECTIN LEVELS IN THALASSEMIC PATIENTS WITH HEPATITIS C TREATED WITH PEGINTERFERON ALPHA-2?
I. Papassotiriou, H. Berdoussi, H. Hantzi, A. Kattamis, C. Kattamis, V. Ladis (Aghia Sophia Children's Hospital, Athens, Greece
 
0005 EFFECTIVENESS AND SAFETY OF LONG-TERM COMBINATION IRON CHELATION THERAPY WITH DESFERRIOXAMINE (DFO) & DEFERIPRONE (DFP) IN MULTITRANSFUSED PATIENTS WITH THALASSAEMIA
S. Fragatos-Pateraki, C. Polotis, K. Vendiadi (3rd Regional Blood Transfusion Centre, Athens, Greece
 
0006 CHELATION EFFICACY OF DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
D. Lee, F. Tricta, Y.C. Tsang, M. Spino (ApoPharma Inc., Toronto, Canada
 
0007 THE ROLE OF RETICULOCYTE HEMOGLOBIN CONTENT (CHR) AS IRON STATUS MARKER IN HAEMODIALYSIS PATIENTS
J.M. Kim, C.H. Ihm, H.J. Kim (Eulji University Hospital, Daejeon, South-Korea
 
0008 SENSITIVITY ANALYSIS ON THE COST-EFFECTIVENESS OF CHELATION THERAPY WITH DEFERASIROX OR DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSEMIA PATIENTS BASED ON EUROPEAN COSTS
E. Delea, O. Sofrygin, J.F. Baladi, S.K. Thomas, P.D. Phatak, T.D. Coates (Policy Analysis Inc. (PAI), Brookline, Ma, USA)
 
0009 BURDEN OF IRON CHELATION THERAPY SIGNIFICANTLY IMPACTS ADHERENCE TO TREATMENT IN PATIENTS WITH IRON OVERLOAD
D. Rofail, M. Viala, E. Trudeau, J.F. Baladi (Mapi Values Ltd, Bollington, United Kingdom)
 
0010 EFFECTS OF SILYMARIN ON TELOMERASE ACTIVITY AND PROLIFERATION OF PERIPHERAL BLOOD T-LYMPHOCYTES IN ß-THALASSEMIA MAJOR PATIENTS?
B. Bagherpour, B. Moayedi, M. Gharagozlu, M. Tahanian, H. Hourfar,
L. Khodadadi, H. Mirmohammadsadeghi (School of Medicine, Isfahan,
Iran)
 
0011 HEPCIDIN MUTATION IN A BETA-THALASSEMIA MAJOR (TM) PATIENT WITH PERSISTENT SEVERE IRON OVERLOAD DESPITE CHELATION THERAPY
L. Duca, P. Delbini, I. Nava, A. Meo, M. La Rosa, L. Zanghì, M.D. Cappellini (University of Milan-Policlinico Hospital, Milan, Italy)
 

ANEMIA / RED BLOOD CELLS I

0012 EARLY MARKERS OF RENAL DYSFUNCTION IN PATIENTS WITH SICKLE CELL / BETA-THALASSEMIA
E. Voskaridou, E. Terpos, S. Michail, E. Hantzi, A. Anagnostopoulos, A. Margeli, D. Simirloglou, D. Loukopoulos, I. Papassotiriou (Thalassemia Center, Laikon Gen. Hospital, Athens, Greece)
 
0013A PHASE I, SINGLE AND FRACTIONATED, ASCENDING DOSE STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF AN ERYTHROPOIETIC MIMETIC ANTIBODY FUSION PROTEIN, CNTO528, IN HEALTHY MALE SUBJECTS
K.L. Franson, J. Burggraaf, E.A. Bouman-Thio, M.B.A. Van Doorn, A.F. Cohen, B.E. Miller, H. Jang, S.J. Marciniak, E.P.S. Van de Ketterij, B. Frederick, Q. Jiao, J. Getsy, E.H. Bald, A. Schantz, J.A. Ford
(CHDR, Leiden, The Netherlands)
 
0014CORRECTION OF ANEMIA OF THE POST-OPERATIVE PERIOD AFTER ORTHOPEDIC SURGERY BY ORAL VERSUS INTRAVENOUS IRON VERSUS INTRAVENOUS IRON + EPO: A PROSPECTIVE
RANDOMIZED TRIAL
P. Beris, F. Verholen, M. Sadowski, M. Noger, P. Hoffmeyer (Geneva University Hospitals, Geneva, Switzerland)
 
0015 A NON-INVASIVE EVALUATION OF HEMATOCRIT WITHA NEW OPTICAL SENSOR
A. Berrebi, O. Amir, A. Weinstein, O. Herzenstein, D. Dvir, E. Monashkin, E. Gabis, P. Holland (Kaplan Medical Center, Rehovot, Israel)
 
0016BODY IRON BALANCE AND IRON EXCRETION: INTAKE RATIO, ACCORDING TO TRANSFUSIONAL REQUIREMENTS, DURING TREATMENT WITH THE ONCE-DAILY ORAL IRON CHELATOR DEFERASIROX (ICL670)
M.D. Cappellini, C. Vermylen, I. Gathmann, J.M. Ford (Universita di Milano, Milan, Italy)
 
0017 EPOETIN BETA 30 000 IU ONCE WEEKLY IS EFFECTIVE AND WELL TOLERATED IN ANEMIC PATIENTS WITH SOLID OR NON-MYELOID HEMATOLOGICAL MALIGNANCIES RECEIVING CHEMOTHERAPY: RESULTS FROM THE NAUTICA STUDY
D. Spaeth, G. Salles, T. Facon, R. Garidi, I. Vaida, P. Fiorentini, L. Bergougnoux (Polyclinique de Gentilly, Nancy, France)
 
0018 PATIENT CONTROLLED ANALGESIA VERSUS CONTINUOUS INFUSION OF MORPHINE DURING VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE: A RANDOMIZED CONTROLLED TRIAL
E.J. van Beers, P.T. Nieuwkerk, C.F.J. van Tuijn, P.W. Friederich, J.H. Franken, B.J. Biemond (Academic Medical Centre, Amsterdam, The Netherlands)
 
0019 EX VIVO ANALYSIS OF PKLR MUTATIONS THAT AFFECT CORRECT PROCESSING OF PKLR MRNA CAUSING PYRUVATE KINASE DEFICIENCY
R. van Wijk, A. van Wesel, G. Rijksen, W.W. van Solinge (University Medical Center Utrecht, Utrecht, The Netherlands)
 
0020 ASSESSMENT OF COGNITIVE EFFECTS OF ONCE-WEEKLY EPOETIN ALFA IN ANEMIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES RECEIVING CHEMOTHERAPY: RESULTS OF THE EPOLYM TRIAL
H. Tesch, A.M. Liberati, N. Ifrah, - Epolym Investigators (Onkologische Gemeinschaftspraxis, Frankfurt, Germany)
 
0021 NON-TRANSFERRIN-BOUND IRON AND OXIDATIVE STRESS ARE RELATED TO THE DEGREE OF ERYTHROPOIESIS IN PATIENTS WITH THALASSAEMIA INTERMEDIA
I. Papassotiriou, C. Lazaropoulou, E. Kanavakis, V. Ladis, G. Paleologos, A. Stamoulakatou, C. Kattamis, A. Kattamis (Aghia Sophia Children's Hospital, Athens, Greece)
 
0022 DEFERASIROX (EXJADE(R), ICL670), THE NOVEL, ONCE-DAILY ORAL IRON CHELATOR, IS WELL TOLERATED AND EFFECTIVE IN TREATING TRANSFUSIONAL IRON OVERLOAD IN PATIENTS WITH A RANGE OF RARE ANAEMIAS
C. Rose, N. Gattermann, E. Glimm, B. Rabault (Hôpital Saint Vincent de Paul, Lille, France)
 
0023 GLYCOCALYX PERTURBATION IN PATIENTS WITH SICKLE CELL DISEASE: IMPLICATIONS FOR VASCULAR VULNERABILITY
E.J. van Beers, M. Nieuwdorp, H. Vink, L.M. Evers, B.J. Biemond (Academic Medical Centre, Amsterdam, The Netherlands)
 
0024 THE DIFFERENTIAL DIAGNOSIS OF INHERITED SIDEROBLASTIC ANAEMIA
A. May, B.C. Kerr, S.D. Whatley, J. Woolf (Cardiff University School of Medicine, Cardiff, United Kingdom)
 
0025 INTRAVENOUS ZOLEDRONIC ACID TREATMENT IN THALASSAEMIA-INDUCED OSTEOPOROSIS: RESULTS OF A PHASE II CLINICAL TRIAL
A . Taher, Z. Otrock, S. Azar, W. Shamseddeen, D. Habr, A. Inati, S. Koussa, R. Mahfouz (American University of Beirut Medical Ct, Beirut, Lebanon)
 
0026 THE DISTINCTION BETWEEN HAEMOLYSIS DUE TO HEREDITARY SPHEROCYTOSIS AND THAT DUE TO A CATION PERMEABILITY DISORDER OF THE RED CELL MEMBRANE IN A REGULAR HAEMATOLOGY LABORATORY
J.S. Goede, R. Rüegg, G.W. Stewart, P. Harrison, H.C. Robinson, T. Latshang, J. Fehr, J.C. Ellory, H.U. Lutz (City Hospital Triemli, Zurich, Switzerland)
 
0027 RITUXIMAB AND FLUDARABINE COMBINATION THERAPY FOR CHRONIC COLD AGGLUTININ DISEASE
S. Berentsen, G.E. Tjonnfjord (Haugesund Hospital, Haugesund, Norway)
 
0028 IN VIVO OXIDATIVE ERYTHROCYTE MEMBRANE PROTEIN DAMAGE IN HEREDITARY SPHEROCYTOSIS
I. Margetis, M. Antonelou, F. Karababa, A. Loutradi, L. Margaritis, I. Papassideri (University of Athens, Athens, Greece)
 
0029 DARBEPOETIN ALFA ADMINISTERED EVERY 3 WEEKS WITH OR WITHOUT PARENTERAL IRON IN ANAEMIC PATIENTS WITH NONMYELOID MALIGNANCIES RECEIVING CHEMOTHERAPY: INTERIM RESULTS FROM A RANDOMISED OPEN-LABEL STUDY
A. Vandebroek, S. Altintas, B. Gaede, K. Smith, B. Yao, M. Schupp (Ziekenhuisnetwerk Antwerpen, Antwerpen, Belgium)
 
0030 CHARACTERISATION OF INDIVIDUAL NADH-CYTOCHROME B5 REDUCTASE VARIANTS USING A HETEROLOGOUS EXPRESSION SYSTEM
M.J. Percy, L.J. Crowley, C.A. Davis, J. Boudreaux, D.M. Layton, M.F. McMullin, T.R.J. Lappin, M.J. Barber (Belfast City Hosptial, Belfast, United Kingdom)
 
0031 DEFERASIROX (ICL670) PROVIDES 24-HOUR PROTECTION FROM LABILE PLASMA IRON (LPI), IN IRON OVERLOADED ß-THALASSAEMIA PATIENTS PREVIOUSLY CHELATED WITH MONO- OR COMBINATION THERAPY
S. Daar, A. Taher, A. Pathare, U. Krahn, C. Ressayre-Djaffer, H. Nick, D. Hadler (Sultan Qaboos University, Muscat, Oman)
 
0032 RESIDUAL IRON LOAD ESTIMATED BY T2* MAGNETIC RESONANCE IN EXTHALASSEMIC PATIENTS LONG-TIME AFTER BONE-MARROW TRANSPLANTATION
V. Ladis, S. Mavrogeni, E. Gotsis, H. Berdousi, F. Petropoulos, A. Kattamis ("Agia Sofia" Children's Hospital, Athens, Greece)
 

A DRUG RESISTANCE & DRUG PHARMACOLOGY

 
0033 GENETIC AND LEUKAEMIA-SPECIFIC FACTORS ASSOCIATED WITH P-GLYCOPROTEIN EXPRESSION AND FUNCTION IN AML BLASTS
C. Seedhouse, M. Grundy, P. White, Y. Li, J. Fisher, D. Yakunina, N. Russell, A. Burnett, M. Pallis (Nottingham City Hospital, Nottingham, United Kingdom)
 
0034 FCGRIIIA 158 V/V GENOTYPE IS ASSOCIATED WITH INFERIOR RESPONSE TO RITUXIMAB AND CHOP IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
Z. Mitrovic, I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, B. Labar (University Hospital Center Zagreb, Zagreb, Croatia)
 
0035 DEFINED BONE MARROW NICHE COMPONENTS MEDIATE THE IN VITRO RESISTANCE OF AML SAMPLES TO THE TYROSINE KINASE INHIBITOR AG1296 AS WELL AS TO CYTOSINE ARABINOSIDE
M. Pallis, U. Mony, D. Cardosa, C. Seedhouse, N. Russel (Nottingham City Hospital, Nottingham, United Kingdom)
 
0036 OVERCOMING CHEMORESISTANCE IN HUMAN CHRONIC MYELOID LEUKEMIA K562 CELLS BY SIRNA INHIBITION OF SHINGOSINE KINASE-1
Y.B. Baran, J.B. Bielawski, C.E.S. Senkal, B.O. Ogretmen, U.G. Gunduz (Middle East Technical University, Ankara, Turkey)
 
0037 DEMONSTRATION OF SYNERGISTIC GROWTH-INHIBITORY EFFECTS OF DASATINIB AND CLADRIBINE IN NEOPLASTIC HUMAN MAST CELLS
K.V. Gleixner, M. Mayerhofer, K. Sonneck, A. Gruze, P. Samorapoompichit, F.Y. Lee, W.F. Pickl, C. Sillaber, P. Valent (Institute of internal medecine, Vienna, Austria)
 
0038 SENSITIZING LEUKEMIC CELLS TO GLUCOCORTICOSTEROIDS BY INHIBITING NFKB ACTIVATION
J. Vink, J. Cloos, R. Oerlemans, C.H. van Zantwijk, J.W. van der Heijden, G. Jansen, G.J.L. Kaspers (VU University Medical Center, Amsterdam, The Netherlands)
 
0039 RAPAMYCIN OVERCOMES DEXAMETHASONE RESISTANCE OF MALIGNANT PLASMA CELLS
F. Bakker, A. Ott, K. Richter, T. Ahrens, R. Burger, A. Guenther, M. Gramatzki (2nd Medical Department, Kiel, Germany)
 
0040 MULTIDRUG RESISTANCE MECHANISMS IN HUMAN CHRONIC MYELOID LEUKEMIA CELLS
Y.B. Baran, A. U. URAL, B.O. Ogretmen, U.G. Gunduz (Middle east Technical University, Ankara, Turkey)
 
0041 IDENTIFICATION AND CHARACTERIZATION OF A HOMO-DIMER OF ABCG2 IN MATURE HUMAN ERYTHROCYTES
M.L. Leimane, E.G. Georges (McGill University, Montreal, Canada)
 
0042 FUNCTIONAL AND GENOME-WIDE ANALYSIS OF ACQUIRED RESISTANCE TO TRAIL/APO2L MEDIATED APOPTOSIS OF HL60 LEUKEMIA CELLS
P. Klener, R. Kralovics, P. Prochazka, A. Vicha, T. Eckschlager, E. Necas, L. Andera, J. Zivny (Charles University, 1st Medical Faculty, Praha, Czech Republic)
 
0043 THE ADMINISTRATION OF REPEATED DOSES OF CYCLOPHOSPHAMIDE, INDUCES CYTOCHROME P450 IN RAT
P. Afsharian, Y. Terelius, Z. Hassan, S. Lundgren, M. Hassan (Karolinska Institutet, Stockholm, Sweden)
 
0044 OPTIMIZATION OF THERAPY FOR THIOPURINE S-METHYLTRANSFERASE DEFICIENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
B. Petrucev, L. Dokmanovic, N. Tosic, D. Janic, N. Jovanovic, S. Pavlovic (IMGGE, Belgrade, Serbia and Montenegro)
 
0045 IMATINIB AND HUMAN ORGANIC CATION TRANSPORTER 1 (HOCT1): CHARACTERISATION OF TRANSPORT IN STABLY TRANSFECTED MYELOID CELLS
A. Giannoudis, L. Wang, R.E. Clark, M. Pirmohamed (University of Liverpool, Liverpool, United Kingdom)
 

MOLECULAR DIAGNOSTICS

0046 PROGNOSTIC SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE (MRD) MONITORING ON RELAPSE-FREE SURVIVAL IN CBFB-MYH11 ACUTE MYELOID LEUKEMIA (AML)
A. Corbacioglu, C. Scholl, K. Eiwen, L. Bullinger, S. Fröhling, H. Döhner, R.F. Schlenk, K. Döhner (University Hospital of Ulm, Ulm, Germany)
 
0047 CHARACTERIZATION OF THREE CASES OF ANEMIA/ MENTAL RETARDATION SYNDROMES (ATR-16) IN THE NETHERLANDS, USING MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA)
C.L. Harteveld, M. Kriek, E.K. Bijlsma, Z. Erjavec, A. Voskamp, D. Balak, P.C. Giordano (Leiden University Medical Center, Leiden, The Netherlands)
 
0048 INDIVIDUAL PATIENT DATA ANALYSIS IN YOUNGER ADULTS WITH NORMAL KARYOTYPE AML: DIFFERENTIAL EFFECTS OF MOLECULAR MARKERS ON CLINICAL OUTCOME. RESULTS OF THE AML STUDY GROUP (AMLSG)
K. Döhner, A. Corbacioglu, J. Krauter, L. Bullinger, D. Späth, I. Schäfer, S. Fröhling, A. Ganser, H. Döhner, R.F. Schlenk (University of Ulm, Ulm, Germany)
 
0049 DEVELOPMENT OF AN INTEGRATED ASSAY FOR QUANTITATIVE REAL TIME DETECTION OF BCR-ABL RNA FROM PERIPHERAL BLOOD
E.S. Winn-Deen, B. Helton, R. Van Atta, W. Wong, J.P. Peralta, J.J. Wang, J. Radich, L. Beppu, G.J. Tsongalis, D.R. Belloni, D. Chan, J.R. Eschelman, C.D. Gocke, Z. Jobbagy (Cepheid, Sunnyvale, Ca, USA)
 
0050 HARMONIZATION OF BCR-ABL TRANSCRIPT QUANTIFICATION USING AN UNIFORM CONTROL PLASMID IN 37 INTERNATIONAL LABORATORIES
M.C. Müller, P. Erben, G. Saglio, E. Gottardi, T. Schenk, T. Ernst, S. Lauber, J. Kruth, R. Hehlmann, A. Hochhaus (Universitätsklinikum Mannheim, Mannheim, Germany)
 
0051 THE IDENTIFICATION OF JAK2V617F IN PATIENTS WITH POLYCYTHAEMIA IS HIGHLY CORRELATED WITH CONVENTIONAL CRITERIA FOR DIAGNOSIS OF POLYCYTHAEMIA VERA
P. Ganly (Christchurch School of Medicine, Christchurch, New Zealand)
 
0052 IDENTIFICATION OF A COMMONLY USED CDR3 REGION OF LGLS TCR ALPHABETA+/CD4+ VBETA 13.1 PATIENTS
P. Garrido, A. Orfao, J. Canton, J. Almeida, M. Lima, P. Barcena, M.A. Lopez- Nevot, F. Garrido, F. Ruiz-Cabello (Virgen de las Nieves Hospital, Granada, Spain)
 
0053 MDR1, MRP AND LRP EXPRESSION IN PATIENTS WITH UNTREATED ACUTE LEUKEMIA: CORRELATION WITH TC-99M MIBI BONE MARROW SCINTIGRAPHY
I. Ak, G. Demirel, Z. Gulbas (Eskisehir Osmangazi University, Eskisehir, Turkey)
 
0054 REAL-TIME RT-PCR ASSAY USING THE TAQMAN PROBES WITH LNA (LOCKED NUCLEIC ACID) MODIFICATION TO DETERMINE JAK2 GENE V617F MUTATIONS IN MYELOPROLIFERATIVE DISEASES (MPD)
J. Marková, J. Schwarz (Institute of Hematology and Blood Transfusion, Prague, Czech Republic)
 
0055 HIGH FREQUENCY OF AML1 MUTATIONS IN BOTH DE NOVO MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA BUT WITH DIFFERENT MUTATION PATTERNS
L.Y. Shih, D.C. Liang, C.F. Huang, J.H. Wu, Y.S. Shih, P.N. Wang, M.C. Kuo, P. Dunn, T.L. Lin, T.C. Tang, H. Chang (Chang Gung Memorial Hospital, Taipei, Taiwan)
 
0056 NPM1 AND FLT3 MUTATIONS, DUPLICATIONS OF MLL AND EXPRESSION OF GENES WT1, EVI AND BAALC AS PROGNOSTIC FACTORS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
S. Ballester, E. Barragán, J. Cervera, P. Bolufer, E. Afan de Ribera, P. Fernandez, R. Andreu, R. Collado, G. MARTÍN, P. Montesinos, J.C. Pajuello, M. Collado, M. Maiques, C. Martin, M.A. Sanz (Hospital La Fe, Valencia, Spain)
 
0057 ACCURATE V617F JANUS KINASE (JAK) 2 MUTATION GENOTYPING COMBINING ARMS PCR AND CAPILLARY ELECTROPHORESIS
F. C. Lambert, A. Schioppa, S. Castermans, M. Lopezy Cadenas, A. Chariot, V. Bours (University of Ličge, Ličge, Belgium)
 
0058 COOPERATING MUTATIONS OF RECEPTOR TYROSINE KINASES AND RAS SIGNALING PATHWAY IN CHILDHOOD CORE-BINDING FACTOR AML WITH EMPHASIS ON C-KIT MUTATION AND A COMPARATIVE STUDY BETWEEN DIAGNOSIS AND RELAPSE
D.C. Liang, L.Y. Shih, C.F. Huang, Y.T. Chang, C.L. Lai, I.J. Hung, C.P. Yang, T.H. Jaing, H.C. Liu, L.Y. Wang, T.C. Yeh (Mackay Memorial Hospital, Taipei, Taiwan)
 
0059 SENSITIVE DETECTION OF C-KIT POINT MUTATIONS IN PATIENTS WITH MASTOCYTOSIS BY D-HPLC
P. Erben, M.C. Müller, T. Schenk, G. Metzgeroth, S. Lauber, J. Kruth, T. Ernst, P. Paschka, R. Hehlmann, A. Reiter, A. Hochhaus (III. Med. Klinik Mannheim University of Heidelberg, Mannheim, Germany)
 
0060 MUTATIONAL SCREENING IN A POPULATION OF HAEMOPHILIA A SUBJECTS FOLLOWED AT THE HAEMOPHILIA CENTRE IN CENTRO HOSPITALAR DE COIMBRA
C. Silva Pinto, T. Fidalgo, D. Marques, E. Gonçalves, P. Martinho, R. Salvado, N. Martins, M.L. Ribeiro (Centro Hospitalar de Coimbra, Coimbra, Portugal)
 
0061 MOLECULAR CLINICAL CORRELATION OF G6PD DEFICIENCY IN WESTERN SAUDI ARABIA
S.K. Al Jaouni (King Abdulaziz University, Jeddah, Saudi Arabia)
 
0062 PREVALENCE OF NMP1 MUTATION IN AML AND MDS
C.E. Lopez Jorge, P. Martin, J. Lopez Brito, M.T. Gomez Casares, J.D Gonzalez San Miguel, A. Lemes, T. Ramirez, G. Santana, R. Mataix, S. De La Iglesia, H. Luzardo, T. Molero (Hospital Universitario Doctor Negrin, Las Palmas De Gran Canaria, Spain)
 
0063 THE COMPARISON OF THE RESULTS OF MOLECULAR MONITORING OF IMATINIB THERAPY IN CML BCR-ABL POSITIVE PATIENTS USING QPCR AND TWO CONTROL REFERENCE GENES
K. Lewandowski, M. Baranska, M. Lewandowska, M. Iwola, D. Drozdowska, J. Rupa, M. Komarnicki (University of Medical Sciences, Poznan, Poland)
 
0064 IMPROVED EFFICIENCY IN MOLECULAR DIAGNOSIS OF T(14;18)(Q32;Q21) AND T(11;14)(Q13;Q32) USING MULTIPLEXAND LONG DISTANCE INVERSE-PCR
L. Vieira, A. Martinho, E. Silva, C. Silva, E. Júnior, P. Jordan (Instituto Nacional de Saúde, Lisboa, Portugal)
 

MOLECULAR TARGETING AND GENE THERAPY

 
0065 THE EFFECT OF HISTONE DEACETYLASE INHIBITORS ON B-CELL DIFFERENTIATION IS NOT UNIQUE FOR TEL-AML1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIAS
M.L. Den Boer, W.A.G. Stams, H.B. Beverloo, E.R. Van Wering, G.E. Janka-Schaub, R. Pieters (Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands)
 
0066 IMATINIB MESYLATE CAN INDUCE MOLECULAR COMPLETE REMISSION IN IDIOPATHIC HYPEREOSINOPHILIC SYNDROME (HES). A PHASE II MULTICENTRIC ITALIAN CLINICAL TRIAL
M. Rondoni, D. Cilloni, E. Ottaviani, PP. Piccaluga, M. Malagola, F. Messa, E. Gottardi, S. Soverini, S. Merante, G. Alimena, F. Pane, S. Paolini, F. Rancati, G. Saglio, M. Baccarani, G. Martinelli (University of Bologna, Bologna, Italy)
 
0067 SIRNA VERSUS LOCKED NUCLEIC ACID RNA ANTAGONISTS: STAY SINGLE!
P. Kearney, M. Westergaard, E.M. Staarup, H.F. Hansen, T. Koch, J.B. Hansen, H. Oerum (Santaris Pharma, Copenhagen, Denmark)
 
0068 DUAL SRC/ABL INHIBITOR SKI-606 BINDING MODE IN BCR-ABL KINASE HYPOTHESIZED ON THE BASIS OF MOLECULAR DOCKING STUDIES
S. Soverini, G. Tasco, T. Grafone, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, F. Palandri, M. Rondoni, A. Poerio, I. Iacobucci, M. Amabile, M. Baccarani, R. Casadio, G. Martinelli (University of Bologna, Bologna, Italy)
 
0069 EFFECTIVE INHIBITION OF BCR/ABL KINASE WITH TETRAMERIZATION DOMAIN DERIVED PEPTIDES MAPES TO COILED-COIL HELIX-ALPHA-2
T. Beissert, V. Kaburova, A. Mian, O.G. Ottmann, D. Hoelzer, M. Ruthardt (University Clinic Frankfurt, Frankfurt, Germany)
 
0070 SINGLE-AGENT SU11657, A NOVEL FLT3 INHIBITOR, SHOWS BIOLOGIC ACTIVITY IN ACUTE MYELOID LEUKEMIA CELLS IN VITRO
T. Grafone, E. Ottaviani, M. Palmisano, M. Mancini, N. Testoni, M. Amabile, C. Terragna, A. Poerio, M. Renzulli, S. Soverini, S. Colarossi, I. Iacobucci, M. Baccarani, G. Martinelli (Inst. of Hematology "Serŕgnoli", Bologna, Italy)
 
0071 POTENTIAL THERAPEUTIC APPROACH OF RECOMBINANT TRAIL IN CML IN BLAST CRISIS
A.C. Gonçalves, A. Oliveira, D. Moreira, C. Costa, J.E. Lopes, C.J. Andrade, T. Silva, V. Alves, M. Dourado, A.B. Sarmento-Ribeiro (Faculty of Medicine of Coimbra, Coimbra, Portugal)
 
0072 RCE1 DEFICIENCY ACCELERATES THE DEVELOPMENT OF A K-RAS INDUCED MYELOPROLIFERATIVE DISEASE
M. Liu, A.M. Wahlstrom, K.M.E. Andersson, C. Karlsson, A.K. Sjögren, B. Cutts, S.G. Young, M. Bergo (Sahlgrenska University Hospital, Gothenburg, Sweden)
 
0073 OPTIMIZING T CELL RECEPTOR GENE TRANSFER TO VIRUS-SPECIFIC T CELLS FOR CLINICAL APPLICATION
M. Griffioen, H.M. van Egmond, M.A.W.G. van der Hoorn, R.S. Hagedoorn, M. Kester, R. Willemze, J.H.F. Falkenburg, M.H.M. Heemskerk (Leiden University Medical Center, Leiden, The Netherlands)
 
0074 DUAL SPECIFIC T CELLS CHANGE THEIR T CELL RECEPTOR (TCR) CELL SURFACE DISTRIBUTION UPON TCR TRIGGERING
M.M. van Loenen, R.S. Hagedoorn, M Hoogeboom, M.G.D. Kester, R. Willemze, J.H.F. Falkenburg, M.H.M. Heemskerk (Leiden University Medical Center, Leiden, The Netherlands)
 
0075 RELEVANCE OF MEK/ERK ACTIVATION IN THE MAINTENANCE OF THE PML/RAR-ALPHA INTEGRITY IN ACUTE PROMYELOCYTIC LEUKEMIA
N. Barbarroja Puerto, E. Siendones Castillo, P. Buendia Bello, L.A. Torres Sanchez, F. Velasco Gimena, A. Torres Gomez, Ch. Lopez Pedrera (Hospital Universitario Reina Sofia, Cordoba, Spain)
 
0076 TRANSCRIPTIONAL PROFILING OF PROTEASOME INHIBITOR-MEDIATED ANTI-TUMOR ACTIVITY IN EPSTEIN-BARR VIRUS-INFECTED NASAL NK LYMPHOMA CELLS
J. Ohyashiki, Y. Zhang, R. Hamamura, N. Shimizu, K. Ohyashiki (Tokyo Medical University, Tokyo, Japan)
 
0077 SIRNA-MEDIATED MLL-AF4 KNOCKDOWN AFFECTS TERT EXPRESSION
J.G. Greil, M. Thomas, P. Gessner, O. Heidenreich (University of Heidelberg, Heidelberg, Germany)
 
0078 PRENYLATION INHIBITORS MODULATE IL-6 AND IGF-1 DEPENDENT SIGNALING IN MULTIPLE MYELOMA CELLS
T. Sebil, D. Peest, A. Ganser, C.W.M. Reuter, M.A. Morgan (Hannover Medical School, Hannover, Germany)
 
0079 EFFECTS OF BORTEZOMIB IN APOPTOSIS IN B-CLL CELLS INDEPENDENTLY OF PRIOR THERAPY - CHARACTERIZATION OF BIOCHEMICAL MECHANISMS ASSOCIATED WITH THE RESPONSE
A.B. Sarmento-Ribeiro, M. Dourado, A.C. Gonçalves, E. Cortesăo, C. Geraldes, L. Rito, I. Sousa, R. Afonso, A. Paiva, A. Pereira, F. Guedes, C. Resende de Oliveira, A. Teixeira (Faculty of Medicine, Coimbra, Portugal)
 
0080 NO EVIDENCE FOR CONSTITUTIVELY ACTIVATED FLT3 IN JUVENILE MYELO-MONOCYTIC LEUKEMIA
A.C.H. de Vries, M.L. den Boer, M.M. van den Heuvel-Eibrink, R. Pieters, P. Schneider, R.W. Stam, E.R. van Wering, C.P. Kratz, C.M. Niemeyer, O.A. Haas (ErasmusMC-Sophia, Rotterdam, The Netherlands)
 
0081 MOLECULAR TARGETS OF THE PROTEASOME INHIBITOR, BORTEZOMIB, ON ADULT T-CELL LEUKEMIA CELLS
R. Hamamura, J. Ohyashiki, T. Takaku, S. Honda, K. Ohyahsiki (Tokyo Medical University, Tokyo, Japan)
 
0082 ANTISENSE THERAPY AGAINST MULTIDRUG RESISTANT GENE (MDR1) IN ACUTE MYELOBLASTIC LEUKEMIA CELL LINE
F. Nadali, A. Pourfathollah, K. Ali-moghaddam, A. Dizaji, A. Zomorodipour, E. Azizi, S. Rostsmi, A. Ghavamzadeh (School of Medicine, Isfahan, Iran)
 
0083 IDENTIFICATION OF HSP-32 = HEME OXYGENASE-1 (HO-1) AS A NOVEL KIT D816V-DEPENDENT TARGET IN NEOPLASTIC MAST CELLS IN SYSTEMIC MASTOCYTOSIS
R. Kondo, M. Mayerhofer, K.V. Gleixner, A. Vales, M.T. Krauth, K.J. Aichberger, S. Derdak, A. Gruze, W. Pickl, C. Sillaber, H. Maeda, P. Valent, K. Greish (Vienna Medical University, Vienna, Austria)
 

CHRONIC MYELOPROLIFERATIVE DISORDERS I

 
0084 EPHA3 TYROSINE KINASE RECEPTORS AS TARGETS IN CHRONIC MYELOPROLIFERATIVE DISEASES
A. Chiarenza, F. Messa, S. Carturan, R. Catalano, F. Arruga, I. Defilippi, V. Rosso, D. Di Giovanni, P. Nicoli, A. Morotti, E. Messa, A. Serra, E. Bracco, G. Saglio, D. Cilloni (University of Turin, Turin, Italy)
 
0085 IDENTIFICATION OF MCL-1 AS A NOVEL TARGET IN NEOPLASTIC HUMAN MAST CELLS: EVIDENCE FOR COOPERATIVE GROWTHINHIBITORY EFFECTS OF MCL-1 ANTISENSE OLIGONUCLEOTIDES, PKC412, AND AMN107
J. Aichberger, M. Mayerhofer, V. Gleixner, T. Krauth, A. Gruze, F. Pickl, V. Wacheck, E. Selzer, H. Agis, C. Sillaber, P. Valent (Medical University of Vienna, Vienna, Austria)
 
0086 ANAGRELIDE: STUDIES ON ITS MODE OF ACTION USING DIFFERENT MODEL SYSTEMS OF MEGAKARYOCYTE DIFFERENTIATION
J.D. Erusalimsky, A. Gutierrez del Arroyo, J. Hernandez, G. Wang, Y. Hong (University College London, London, United Kingdom)
 
0087 TISSUE-PLASMINOGEN ACTIVATOR (T-PA) AND PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
R. Cacciola (Institute of Hematology, Catania, Italy)
 
0088 PLATELET, LEUKOCYTE AND COAGULATION ACTIVATION PATTERNS IN MYELOFIBROSIS WITH MYELOID METAPLASIA
A. Alvarez-Larrán, E. Arellano-Rodrigo, J.C. Reverter, N. Villamor, D. Colomer, A. Domingo, R. Vallansot, F. Cervantes, E. Arellano-Rodrigo, J.C. Reverter, N. Villamor, D. Colomer, A. Domingo, R. Vallansot, F. Cervantes (Hospital Clínic, Barcelona, Spain)
 
0089 EPIGENETIC ALTERATIONS AND MUTATION OF JAK2 TYROSINE KINASE IN PATIENTS WITH BCR/ABL NEGATIVE MYELOPROLIFERATIVE DISORDERS
E.B. Jost, N. do Ň, E. Dahl, C. Maintz, P. Jousten, L. Habets, J.G. Herman, S. Wilop, R. Osieka, O. Galm (UK Aachen, Aachen, Germany)
 
0090 CLINICOPATHOLOGIC HETEROGENEITY OF CHRONIC HYPEREOSINOPHILIC SYNDROMES -LONG-TERM EXPERIENCE ON 32 PATIENTS
G. Helbig, B. Stella-Holowiecka, S. Grosicki, M.K. Krawczyk, G.B. Bober, A.B. Baranski, I.K. Kniewska, J.M. Mazurek, J.P. Pajak, A.B.C. Bartkowska-Chrobok, J.H. Holowiecki (Silesian Medical University, Katowice, Poland)
 
0091 APPLICATION OF PRV-1 MRNA EXPRESSION LEVEL AND JAK2- V617F MUTATION FOR DIFFERENTIAL DIAGNOSTICS BETWEEN POLYCYTHEMIA VERA AND SECONDARY ERYTHROCYTOSIS. INFLUENCE OF INTERFERON THERAPY ON PRV-1 EXPRESSION
V.V. Tutaeva, M.A. Sokolova, N.V. Tsvetaeva, E.A. Semenova, V.L. Ivanova, T.I. Kolosheinova, A.V. Misurin, N.D. Khoroshko (Hematology Research Centre RAMS, Moscow, Russian Federation)
 
0092 INFLUENCE OF LONG TERM HYDROXYUREA TREATMENT ON PRV-1 EXPRESSION LEVEL IN POLYCYTHEMIA VERA PATIENTS
V.V. Tutaeva, M.A. Sokolova, N.V. Tsvetaeva, E.A. Semenova, V.L. Ivanova, T.I. Kolosheinova, A.V. Misurin, N.D. Khoroshko (Hematology Research Centre RAMS, Moscow, Russian Federation)
 
0093 V617F JAK2 MUTATION IN CHILDREN WITH ESSENTIAL THROMBOCYTHEMIA (ET)
M.L. Randi, M.C. Putti, M. Scapin, E. Pacquola, F. Fabris (University of Padua, Padova, Italy)
 
0094 PREVIOUS HISTORY OF THROMBOTIC COMPLICATION IS THE MAIN RISK FACTOR THAT INCREASES THE INCIDENCE OF THROMBOTIC EVENTS IN ESSENTIAL THROMBOCYTHEMIA PATIENTS
F. Radaelli, M. Colombi, V.R. Zilioli, S. Bramanti, A. Iurlo, A. Zanella (Ospedale Maggiore Policlinico, Mangiagal, Milano, Italy)
 
0095 RATIONALE AND DESIGN OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE CORTICOSTEROID-SPARING EFFECTS OF ANTI-IL5 MONOCLONAL ANTIBODY (MEPOLIZUMAB) IN SUBJECTS WITH HYPEREOSINOPHILIC SYNDROME (HES)
X. Parkin, M. Rothenberg, F. Roufosse, A. Klion, J. Denburg, J. Murray, L. Rosenwasser, L. Schwartz, P. Weller, K. Leiferman, A. Haig, G. Gleich (GlaxoSmithKline, Middlesex, United Kingdom)
 
0096 FIP1L1-PDGFRA+ HYPEREOSINOPHILIA: HOW MANY DISEASES ?
F.C. Lambert, L. De Leval, C. Herens, A. Chariot, V. Bours (University of Ličge, Ličge, Belgium)
 
0097 VEGF SERUM LEVELS AND VEGF BONE MARROW IMMUNOHISTOCHEMICAL EXPRESSION IN CHRONIC MYELOPROLIFERATIVE DISORDERS
K. Panteli, M. Bai, N. Zagorianakou, L. Bourantas, E. Hatzimichael, K. Bourantas (University of Ioannina, Ioannina, Greece)
 
0098 ARRAY COMPARATIVE GENOMIC HYBRIDIZATION REVEALS AN ABSENCE OF RECURRENT GENOMIC COPY NUMBER CHANGES IN ESSENTIAL THROMBOCYTHEMIA
B. Espinet, E. Puigdecanet, L. Florensa, E. González, M. Salido, B. Bellosillo, M.E. Pérez-Vila, C. Pedro, L. Sumoy, C. Besses, S. Serrano, F. Solé (Hospital del Mar, Barcelona, Spain)
 
0099 THE INCIDENCE OF DEL20Q12 BY INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION (I-FISH) IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS
L. Pantelidou, I. Bazdiara, G. Trypsianis, D. Margaritis, G. Xanthopoulidis, A. Anastasiadis, M. Baka, V. Kaloutsi, G. Bourikas, C. Tsatalas (Democritus University of Thrace, Alexandroupolis, Greece)
 
0100 ABNORMAL EXPRESSION OF THE WAP FAMILY SLPI GENE IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS
E. Antonioli, A. Pancrazzi, P. Guglielmelli, C. Bogani, A. Bosi, A.M. Vannucchi (Az Ospedaliero-Univarsitaria Careggi, Florence, Italy)
 
0101 CONGENITAL ERYTHROCYTOSIS AND POLYCYTHEMIA VERA IN CHILDREN AND ADOLESCENTS - AN ONLINE DATABASE FOR REGISTRATION OF PATIENTS AND DATA COLLECTION
M.C. Bento, H. Cario, J. Vidan, A. Villegas, M.L. Ribeiro (Centro Hospitalar Coimbra, Coimbra, Portugal)
 
0102 ERYTHROCYTOSIS AND THROMBOCYTOSIS IN CHILDHOOD: THE EXPERIENCE OF A SINGLE CENTRE.
U. Ramenghi, P. Quarello, D. Renga, A. Doria, S. Martino, L. Foglia, L. Alba, S. Carturan, P. Sterpone, F. D'Arajo, L. Garbarini, L. Farinasso (University of Torino, Torino, Italy)
 
0103 PREDICTIVE VALUE OF ALTERATIONS OF COAGULATION AND THE JAK2 MUTATION ON THE RISK OF THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA
C.B. Burgaleta, D. de Miguel, M. Lopez Rubio, C.B. Besses, B.B. Bellosillo, T.P. Pascual, B. Paramio, J. García Suárez, H.B. Bańas, C.P. Perez Calvo (Hospital U. Principe de Asturias, Alcalá De Henares, Spain)
 

ACUTE MYELOID LEUKEMIA I

 
0104 MOLECULAR PROFILING USING ARRAY-CGH AND GENE EXPRESSION PROFILING REVEALS NEW CANDIDATE GENES IN AML WITH NORMAL KARYOTYPE
F.G. Rücker, L. Bullinger, H.A. Kestler, P. Lichter, K. Döhner, A.A. Quirino, H. Döhner (University of Ulm, Ulm, Germany)
 
0105 CO-EXPRESSION OF CD34, MDR1 AND BCRP INDICATES A CLINICALLY RESISTANT PHENOTYPE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OF OLDER AGE.
M.M. van den Heuvel-Eibrink, B. van der Holt, P.J.M. Vossebeld, A.K. Burnett, W.U. Knauf, P.P. Piccaluga, M.F. Fey, G.E.G. Verhoef, E. Vellenga, G.J. Ossenkoppele, B. Lowenberg, P. Sonneveld (Erasmus Medical Center-Sophia, Rotterdam, The Netherlands)
 
0106 REPLICATIVE SENESCENCE INDUCTION IN GOOD-RISK ACUTE MYELOID LEUKEMIA
J.M. Zijlmans, S.J.J. Swiggers, H.B. Beverloo, B. Löwenberg, (Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands)
 
0107 PROGNOSTIC IMPACT OF FLOW CYTOMETRICALLY DETERMINED MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
W. Kern, D. Voskova, C. Schoch, S. Schnittger, T. Haferlach (MLL Munich Leukemia Laboratory, Munich, Germany)
 
0108 PROGNOSTIC RELEVANCE OF FLT3-TKD MUTATIONS IN AML: THE COMBINATION MATTERS- AN ANALYSIS OF 3082 PATIENTS
S. Schnittger, U. Bacher, C. Schoch, W. Kern, T. Haferlach (MLL, Munich, Germany)
 
0109 EXPRESSION OF TUMOR-ASSOCIATED ANTIGENS IN ACUTE MYELOID LEUKEMIA AND THEIR CORRELATION WITH SURVIVAL
M. Schmitt, J. Greiner, L. Li, K. Giannopoulos, K. Boesch, K. Döhner, R.F. Schlenk, J.R. Pollack, H. Döhner, L. Bullinger (University of Ulm, Ulm, Germany)
 
0110 PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS <60 YEARS WITH TRISOMY 8 AS A SOLE ABERRATION: POOLED DATA ANALYSIS OF THE GERMAN ACUTE MYELOID LEUKEMIA INTERGROUP
M. Schaich, R.F. Schlenk, H. Döhner, A. Ganser, G. Heil, T. Illmer, R. Krahl, J. Krauter, D. Niederwieser, C. Sauerland, S. Soucek, T. Büchner, G. Ehninger (Universitätsklinikum C.G.Carus, Dresden, Germany)
 
0111 PROGNOSTIC IMPACT OF THE NPM1/FLT3 ITD MUTATION STATUS IN ELDERLY PATIENTS (>60 YEARS OF AGE) WITH NORMAL KARYOTYPE AML: RESULTS OF AMLSG TREATMENT TRIAL AML HD98B
K. Döhner, A. Corbacioglu, B. Krebs, S. Hein, L. Bullinger, S. Fröhling, H. Döhner, R.F. Schlenk (University of Ulm, Ulm, Germany)
 
0112 PROGNOSTIC DETERMINANTS IN ADULT AML PATIENTS WITH INTERMEDIATE RISK KARYOTYPE
F. Buccisano, L. Maurillo, G. Del Poeta, M.I. Del Principe, P. Panetta, D. Fraboni, M. Mazzone, L. Gianně, S. Campagna, D. Renzi, C. Sarlo, L. Franceschini, V. Gattei, F. Lo Coco, S. Amadori, A. Venditti (Tor Vergata University Hospital, Rome, Italy)
 
0113 ROLE OF DNA METHYLTRASFERASES (DNMTS) AND POLYCOMB GROUP OF PROTEINS (PCG) IN LEUKEMIA
L. Di Croce (Centre for Genomic Regulation, Barcelona, Spain)
 
0114 TRISOMY 8 AS SOLE ANOMALY OR WITH OTHER CLONAL ABERRATIONS IN ACUTE MYELOID LEUKEMIA: IMPACT ON CLINICAL PRESENTATION AND TREATMENT OUTCOME
X. Thomas, N. Jaff, Y. Chelghoum, M. Elhamri, I. Tigaud, M. Michallet (Edouard Herriot Hospital, Lyon, France)
 
0115 ANALYSIS OF 1458 ACUTE MYELOID LEUKEMIA FROM THE ALERT PROJECT (ACUTE LEUKEMIA CLINICAL REGISTER) IN THE CZECH REPUBLIC IN 1996-2006
I.K. Indrak, D.M. Doubek, V.J. Voglová, K.V. Koza, K.T. Kozák, S.T. Szotkowski, M.J. Mayer, Z.P. Z? ák, C.P. Cetkovsk´y, M.K. Michalová, J.M. Jaros? ová, S.K. Steinerová, M.J. Muz? ík, D.L. Dus? ek, M.J. Maaloufová (University Hospital, Olomouc, Czech Republic)
 
0116 CLORETAZINE(R)‚ (VNP40101M) HAS SIGNIFICANT ACTIVITY AS INDUCTION THERAPY FOR ELDERLY PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR ADVANCED MYELODYSPLASTIC SYNDROME (MDS)
J. Giles, D. Rizzieri, J. Karp, K.D. Khan, G. Mufti, G. Verhoef, P.W. Wijermans, A. Advani, V. Karsten, R. Geller, S. O'Brien, N. Vey (MD Anderson Cancer Center, Houston, USA)
 
0117 DOSING OF TROXATYL (TROXACITABINE, SGX-145) BASED ON RENAL FUNCTION
M.J. Kelner, J. Giles, J. Feldman, J. Roboz, J. DeAngelo, A. Lokker, K. Burley (University of California, San Diego, San Diego, USA)
 
0118 CYTOGENETIC RESPONSES IN OLDER PATIENTS WITH AML AND COMPLEX KARYOTYPE TREATED WITH LOW- DOSE 5-AZA-2'- DEOXYCYTIDINE (DECITABINE)
B. Rüter, S. Knipp, U. Germing, M. Lübbert (University of Freiburg, Freiburg, Germany)
 
0119 SINGLE POINT MUTATIONS IN THE JUXTAMEMBRANE DOMAIN OF FLT3 ARE RARELY FOUND IN AML PATIENTS AND DEFINE THE THIRD CLASS OF ACTIVATING MUTATIONS
C. Reindl, K. Bagrintseva, S. Vempati, S. Schnittger, J.W. Ellwart, K. Wenig, K.P. Hopfner, W. Hiddemann, K. Spiekermann (GSF-Hämatologikum, Munich, Germany)
 
0120 ORIGINAL DATA BASED META-ANALYSIS ON PATIENTS >60 YEARS OF AGE WITH CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA - RESULTS OF THE GERMAN AMLINTERGROUP
R.F. Schlenk, R. Krahl, C. Sauerland, T. Büchner, S. Soucek, M. Schaich, G. Ehninger, A. Ganser, K. Döhner, H. Döhner, D. Niederwieser (University of Ulm, Ulm, Germany)
 
0121 THE KINETICS OF REDUCTION OF MINIMAL RESIDUAL DISEASE IMPACTS ON DURATION OF RESPONSE AND SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
F. Buccisano, L. Maurillo, G. Del Poeta, M.I. Del Principe, P. Panetta, M. Mazzone, D. Fraboni, G. De Angelis, M. Postorino, M. Ales, R. Cerretti, M. Rizzo, V. Gattei, F. Lo Coco, S. Amadori, A. Venditti (Tor Vergata University Hospital, Rome, Italy)
 
0122 CLOFARABINE AS FIRST-LINE TREATMENT OF ELDERLY (>= 65 YEARS OF AGE) AML PATIENTS WITH AN UNFAVOURABLE CYTOGENETIC PROFILE WHO ARE UNSUITABLE FOR STANDARD TREATMENT
A.K. Burnett, M. Baccarani, P. Johnson, J. Yin, N. Russell (University of Wales College of Medicine, Cardiff, United Kingdom)
 
0123 ABCB1 (PGP) AND ABCG2 (BCRP) PROTEINS ARE INDEPENDENT PROGNOSTIC FACTORS FOR COMPLETE REMISSION AND RELAPSE RISK, RESPECTIVELY, IN NORMAL KARYOTYPE ADULT DE NOVO ACUTE MYELOID LEUKEMIA
M. Tiribelli, D. Damiani, E. Calistri, A. Geromin, A. Chiarvesio, A. Michelutti, M. Cavallin, R. Fanin (Division of Hematology and BMT, Udine, Italy)
 

ACUTE MYELOID LEUKEMIA II

 
0124 IMMUNOPHENOTYPIC PATTERN OF HIGH RISK KARYOTYPE ACUTE MYELOID LEUKEMIA IS CHARACTERIZED BY EXPRESSION OF CD34 AND LACK OF MPO
M. Sierra, M.B. Vidriales, J.J. Pérez, N.C. Gutierrez, I. Recio, R. Cuello, F. Ramos, A. Martin-Sancho, J.A. Rodriguez, J.L. Garcia, J.M. Hernandez, J.F. San Miguel (Hospital Clinico U. Salamanca, Salamanca, Spain)
 
0125 ABNORMALITIES IN P53 AND P14ARF IN DE NOVO AML PREDICTS A VERY SHORT OVERALL SURVIVAL AND IN VITRO DRUG-RESISTANCE.
H. Nahi, M. Merup, S. Lehmann, S. Bengtzen, M. Jansson, L. Möllgĺrd, C. Paul (Karolinska University Hospital, Stockholm, Sweden)
 
0126 LEUKEMIA IN UKRAINIAN CLEAN-UP WORKERS OF THE CHERNOBYL ACCIDENT: EPIDEMIOLOGIC AND HEMATOLOGIC ASPECTS
D. Bazyka, A. Romanenko, D. Bazyka, V. Bebeshko (Research Center for Radiation Medicine, Kyiv, Ukraine)
 
0127 QUANTITATIVE ASSESMENT OF AML/ETO FUSION TRANSCRIPT AS USEFUL TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION AND OUTCOME PREDICTION IN T(8;21) AMLS
E. Messa, D. Cilloni, E. Ottaviani, M. Fava, E. Gottardi, F. Messa, F. Arruga, I. Defilippi, P. Nicoli, S. Carturan, A. Guerrasio, G. Martinelli, G. Saglio (University of Turin, Orbassano, Italy)
 
0128 PROGNOSTIC SIGNIFICANCE OF BAALC EXPRESSION IN ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: FROM MICROARRAY TO RQPCR ASSAY
N. Maroc, O. Biglia, V. Forestier, A. Martinec, N. Borie, N. Carbuccia, N. Vey, D. Birnbaum, M.J. Mozziconacci, F. Hermitte (Ipsogen, Marseille, France)
 
0129 A MULTICENTER PROSPECTIVE RANDOMIZED STUDY OF LENOGRASTIM (RHG-CSF) IN CONSOLIDATION CHEMOTHERAPY FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (JALSG GML200-S STUDY)
S. Ohtake, F. Yagasaki, S. Miyawaki, M. Matsuda, H. Taguchi, T. Matsushima, K. Toba, M. Yoshida, T. Naoe, R. Ueda, R. Ohno (Kanazawa University, Kanazawa, Japan)
 
0130 INTERPRETATION OF INTERLEUKIN-2 RECEPTOR ALPHA POSITIVE CELLS DURING INDUCTION CHEMOTHERAPY FOR ADULT ACUTE MYELOGENOUS LEUKEMIA PATIENTS
H.J. Kim, H.Y. Jeong, Y. Choi, S.Y. Kim, K.S. Eom, S. Lee, C.K. Min, S.G. Cho, J.W. Lee, W.S. Min, C.C. Kim (CHSCTC,Catholic Univ. of Korea, Seoul, South-Korea)
 
0131 INHIBITION OF FLT3-ACTIVATING MUTATIONS MAY NOT PREVENT CONSTITUTIVE ACTIVATION OF ERK/AKT/STAT PATHWAYS IN SOME AML SAMPLES: A POSSIBLE CAUSE FOR THE LIMITED EFFECTIVENESS OF THERAPY WITH SMALL-MOLECULE INHIBITORS
C.H. Lopez-Pedrera, E. Siendones, N. Barbarroja, P Buendia, A Torres, F Velasco (Hospital "Reina Sofia", Cordoba, Spain)
 
0132 THE PRESENCE OF FLT3 MUTATIONS DOES NOT IMPAIR STEM CELL MOBILIZATION AND FEASIBILITY OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA
F. Ferrara, S. Palmieri, F. Pollio, C. Lo Pardo, D. Graziano, C. Falco, M.R. D'Amico, M. Celentano, L. Vicari, B. Izzo, F. Pane (Cardarelli Hospital, Napoli, Italy)
 
0133 MYELOABLATIVE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL INFUSION MAY OVERCOME THE ADVERSE PROGNOSTIC IMPACT OF FLT3 MUTATIONS IN ACUTE MYELOID LEUKAEMIA
F. Ferrara, S. Palmieri, F. Leoni, S. Ciolli, M.R. D'Amico, F. Pollio, M. Celentano, B. Izzo, F. Pane (Cardarelli Hospital, Napoli, Italy)
 
0134 PEDIATRIC RELAPSED ACUTE MYELOID LEUKEMIA (AML) IN THE NETHERLANDS FROM 1980 UNTIL 2000
B.F. Goemans, K. Corbijn, R.Y.J. Tamminga, K. Hahlen, G.J.L. Kaspers (VU university Medical Center, Amsterdam, The Netherlands)
 
0135 PROTEIN KINASE CK2ALPHA AS AN INDEPENDENT PROGNOSTIC MARKER AND A NOVEL THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA
Y.H. Min, J.I. Eom, J.Y. Cho, J.W. Cheong, J.S. Kim, Y.R. Kim, I.H. Park, J.K. Lee, W.I. Yang (Yonsei Universtiy College of Medicine, Seoul, South-Korea)
 
0136 INTERLEUKIN-2 CAN BE SAFELY ADMINISTERED TO AML PATIENTS IN 1ST CR AFTER AN AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
S.M. Trisolini, S. Capria, L. Cardarelli, V. Gianfelici, G.A. Natale, M. Ribersani, F. Mandelli, R. Foŕ, G. Meloni (La Sapienza University, Roma, Italy)
 
0137 STEM CELL DETECTION IN AML PATIENTS UNDER REMISSION CONDITIONS: A NEW ERA IN MINIMAL RESIDUAL DISEASE DETECTION?
A. van Rhenen, N. Feller, A. Kelder, B. Moshaver, A.H.W. Westra, S. Zweegman, G.J. Ossenkoppele, G.J. Schuurhuis (VU University Medical Center, Amsterdam, The Netherlands)
 
0138 ANALYSIS OF X-CHROMOSOME INACTIVATION PATTERNS IN IRANIAN PATIENTS WITH AML DURING REMISSION
Y. Mortazavi, S. Kaviani, K. Alimoghaddam, A.A. Pourfathollah (Zanjan Medical School, Zanjan, Iran)
 
0139 PROGNOSTIC ROLE OF EOSINOPHILIA AND CYTOGENETICS ON TREATMENT RESPONSE AND SURVIVAL IN AML-M4. THE GIMEMA EXPERIENCE
A. Pulsoni, S. Iacobelli, A. Matturro, P. Fazi, M. Vignetti, F. Ferrara, F. Di Raimondo, M. Sborgia, A. Venditti, A. Camera, G. Specchia, G. Leone, F. Mandelli, R. Foa', L. Pagano (La Sapienza University, Rome, Italy)
 
0140 POLYMORPHISMS IN THE RAD51 AND XRCC-3 GENES INCREASE THE RISK OF DEVELOPING ACUTE MYELOID LEUKAEMIA
E. Fabiani, F. Guidi, F. D'Alo', M. Giachelia, D. Gumiero, G. Leone, M.T. Voso (Universita' Cattolica S. Cuore, Rome, Italy)
 
0141 THE ANTI-PROLIFERATIVE AND APOPTOSIS-INDUCING EFFECTS OF THE PROTEASOME INHIBITORS BORTEZOMIB AND PR-171 IN ACUTE MYELOGENOUS LEUKAEMIA
C. Stapnes, A. Dřskekand, K.J. Hatfield, E. Ersvćr, B.T. Gjertsen, Ř. Bruserud (Institute of Medicine, Bergen, Norway)
 
0142 SINGLE CELL ANALYSIS OF PHOSPHOINOSITIDE 3-KINASE/AKT AND ERK ACTIVATION IN ACUTE MYELOID LEUKEMIA BY FLOW CYTOMETRY
V. Bardet, J. Tamburini, N. Ifrah, F. Dreyfus, P. Mayeux, C. Lacombe, D. Bouscary (Institut Cochin, Paris, France)
 

CHRONIC MYELOID LEUKEMIA I

 
0143 ABERRANT EXPRESSION OF CELLULAR RETINOL-BINDING PROTEIN-1 (CRBP-1) IN MEGAKARYOCYTES AND MARROW STROMA CELLS OF CHRONIC MYELOPROLIFERATIVE AND MYELODYSPLASTIC/MYELOPROLIFERATIVE DISORDERS
A.H. Schmitt-Graeff, M. Lübbert, C. F. Waller, M.L. Bochaton-Piallat, G. Gabbiani (Institute of Pathology Universityhospit, Freiburg, Germany)
 
0144 CHRONIC MYELOID LEUKEMIA (CML) CELLS EXPRESS TUMOR ASSOCIATED ANTIGENS ELICITING SPECIFIC CD8+ T CELL RESPONSES AND ARE LACKING COSTIMULATORY MOLECULES
L. Li, A. Schmitt, J. Chen, K. Giannopoulos, C. Brunner, K. Döhner, H. Döhner, J. Greiner (University of Ulm, Ulm, Germany)
 
0145 MOLECULAR RESPONSE AT 6 MONTHS IS A GOOD EARLY PREDICTOR OF DURATION OF TREATMENT RESPONSE IN IMATINIBTREATED CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA (CML)
M. Ross, S. Branford, J. Reynolds, R. Koelmeyer, T.P. Hughes (IMVS, Adelaide, Australia)
 
0146 BCR-ABL PEPTIDE VACCINATION INDUCES ADDITIONAL MOLECULAR IMPROVEMENT IN IMATINIB-RESPONSIVE CHRONIC MYELOID LEUKAEMIA (CML)
L. Wang, J. Rojas, K. Knight, C. Lucas, R. Clark (Royal Liverpool University Hospital, Liverpool, United Kingdom)
 
0147 P210 BCR-ABL TYROSINE KINASE INTERACTS WITH HISTONE DEACETYLASE 1 IN CHRONIC MYELOID LEUKAEMIA HAEMATOPOIETIC PROGENITORS: CONSEQUENCES ON HISTONE H4 ACETYLATION AND CHROMATIN STRUCTURE
G. Brusa, M. Mancini, E. Zuffa, P. Corrado, S. Luatti, E. Barbieri, M.A. Santucci (Universitŕ di Bologna, Bologna, Italy)
 
0148 BCR/ABL ONCOGENIC KINASE DISRUPTS MISMATCH RECOGNITION AND REPAIR COMPLEX TO INDUCE GENOMIC INSTABILITY
T. Stoklosa, A. Slupianek, G. Basak, T. Skorski (The Medical University of Warsaw, Warsaw, Poland)
 
0149 COMPARATIVE PROTEOMIC ANALYSIS OF CHRONIC MYELOGENOUS LEUKEMIA CELLS : INSIDE THE MECHANISM OF IMATINIB RESISTANCE
V. Santini, G. Ferrari, A. Gozzini, R. Pastorelli (University of Florence, Firenze, Italy)
 
0150 DASATINIB (D) IN PATIENTS (PTS) WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN MYELOID BLAST CRISIS (MBC) THAT IS IMATINIB-RESISTANT (IM-R) OR IM-INTOLERANT (IM-I): RESULTS OF THE CA180006 'START-B' STUDY
M. Baccarani, J. Cortes, D.W. Kim, T. Facon, J.F. Apperley, P. Rousselot, E. Bleickardt, R. Zink, M. Muller, C. Sawyers (University of Bologna, Bologna, Italy)
 
0151 A PHASE II STUDY OF NILOTINIB (AMN107), A NOVEL INHIBITOR OF BCR-ABL, ADMINISTERED TO IMATINIB-RESISTANT OR INTOLERANT PATIENTS WITH PH+ CHRONIC MYELOGENOUS LEUKEMIA (CML) IN BLAST CRISIS (BC) OR RELAPSED/ REFRACTORY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
O.G. Ottmann, R. Larson, P. Le Coutre, M. Baccarani, T. Rafferty, L. Alland, H. Kantarjian, T. Hughes, F. Giles (University of Frankfurt, Frankfurt, Germany)
 
0152 A STUDY OF BCR-ABL MUTATIONS IN PATIENTS WITH IMATINIBRESISTANT CML AND PH+ALL PATIENTS ENROLLED IN A NILOTINIB (AMN107) PHASE I STUDY
J. Giles, K. Bhalla, H. Kantarjian, A. Hochhaus, M. Muller, D. Jones, K. Dawson, K. Rose, L. Alland, M. Dugan, S. Lilleburg, O. Ottman (MD Anderson Cancer Center, Houston, USA
 
0153 ROLE OF ENDOTHELIAL PROGENITOR CELLS IN MYELOPROLIFERATIVE DISEASES
C. Zwicky, E. Oppliger Leibundgut, M.P. Horn, C. Brunold, B. Pfanner-Meyer, D. Marti, H. Hirsiger, A. Tobler, G. Baerlocher (University Berne, Berne, Switzerland)
 
0154 COMPLIANCE AND PERSISTENCY WITH IMATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS
W. Feng, J. Henk, K. Thomas, J. Baladi, A. Hatfield, A. Goldberg, J. Cortes (Novartis Pharmaceuticals Corporation, Florhem Park, USA)
 
0155 COMPARISON BETWEEN CONVENTIONAL AND MOLECULARLY DEFINED THERAPEUTICS IN A CONDITIONAL BCR-ABL CELL CULTURE MODEL
A. Chaturvedi, K. Battmer, M. Scherr, M. Eder, A. Ganser (Hannover Medical school, Hannover, Germany)
 
0156 A PHASE II STUDY OF NILOTINIB (AMN107) A NOVEL INHIBITOR OF BCR-ABL, ADMINISTERED TO IMATINIB-RESISTANT OR INTOLERANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML) IN ACCELERATED PHASE (AP)
H. Kantarjian, O. Ottmann, N. Gattermann, R. Larson, T. Rafferty, L. Alland, F. Giles, S.G. O'Brien, P. Le Coutre (The University of Texas MD Anderson Canc, Houston, USA)
 
0157 IMATINIB 800 MG IN INTERMEDIATE SOKAL RISK PATIENTS IN EARLY CHRONIC PHASE: RESULTS OF A PHASE II TRIAL OF THE GIMEMA CML WORKING PARTY
G. Rosti, F. Castagnetti, M. Amabile, N. Testoni, G. Marzocchi, M. Breccia, F. Palandri, C. Bigazzi, A. Poerio, F. Stagno, F. Iuliano, E. Abruzzese, F. Pane, G. Saglio, G. Martinelli, M. Baccarani (University of Bologna, Bologna, Italy)
 
0158 PHILADELPHIA-POSITIVE HEMATOPOIETIC PROGENITORS ARE NOT DETECTABLE IN CML PATIENTS TREATED WITH IMATINIB ACHIEVING A MAJOR MOLECULAR RESPONSE
A. Ibatici, M. Podesta, G. Fugazza, N. Sessarego, A. Garuti, S. Pozzi, M. Corselli, F. Bertolotti, M. Sessarego, F. Patrone, F. Frassoni (Ospedale San Martino, Genova, Italy)
 
0159 DASATINIB (D) IN PATIENTS (PTS) WITH ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (AP-CML) RESISTANT OR INTOLERANT TO IMATINIB: RESULTS OF THE CA180005 'START-A' STUDY
F. Guilhot, J.F. Apperley, A. Hochhaus, R. Silver, S. Amadori, A. Gratwohl, S. Cheng, M. Iyer, J. Radich, M. Talpaz (CHU La Miletrie, Poitiers, France)
 
0160 INVOLVEMENT OF RAS, JAK2 AND GM-CSF IN THE PATHOGENESIS OF PROLIFERATIVE VARIANT OF CHRONIC MYELOMONOCYTIC LEUKEMIA
F. Onida, F. Servida, C. Ricci, E. Fermo, M.C. Pasquini, A. Vismara, A. Cortelezzi, S. Soligo, G. Lambertenghi-Deliliers (Matarelli Foundation for Blood Diseases, Milano, Italy)
CHRONIC MYELOID LEUKEMIA II

 
0161 TRANSCRIPTIONAL PROFILING OF PRIMARY IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA
O. Frank, B. Brors, A. Fabarius, L. Li, C. Zheng, M.C. Müller, R. Hehlmann, A. Hochhaus, W. Seifarth (Universität Heidelberg, Mannheim, Germany)
 
0162 MONITORING SERUM LEVELS OF IMATINIB AND HAEMATOLOGICAL TOXICITY IN CML PATIENTS
M. Perez-Abad, J. Perez-Oteyza, M.I. Arranz Peńa, J. Lopez Jimenez, J. Garcia Larańa, E. Ripoll Sevillano (Ramon y Cajal Hospital, Madrid, Spain)
 
0163 IMATINIB PRECEDING ALLOGENEIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID LEUKAEMIA
J.B. Perz, D. O`Shea, J. Sanz, A. Chaidos, J. Kaeda, D. Marin, E. Eduardo, J.F. Apperley (University Heidelberg, Heidelberg, Germany)
 
0164 EARLY OR LATE COMPLETE MOLECULAR REMISSIONS IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED WITH IMATINIB RELY ON THE SPEED TO ACHIEVE A COMPLETE CYTOGENETIC REMISSION (CCR) STATUS AND ON EARLY QUANTITATIVE BCR-ABL LEVELS
F.E. Nicolini, E. Bachy, S. Corm, C. Plesa, Q.H. Lę, S. Hayette, C. Preudhomme, M. Michallet (Edouard Herriot Hospital, Lyon, France)
 
0165 THE IMPACT OF NON-COMPLIANCE WITH IMATINIB THERAPY ON HEALTH CARE COSTS IN CHRONIC MYELOID LEUKEMIA PATIENTS
W. Feng, J. Henk, K. Thomas, J. Baladi, A. Hatfield, A. Goldberg, J. Cortes (Novartis Pharmaceuticals Corporation, Florhem Park, USA)
 
0166 MOLECULAR RESPONSE TO IMATINIB IN EARLY CHRONIC PHASE VERSUS LATE CHRONIC PHASE CML PATIENTS IN COMPLETE CYTOGENETIC RESPONSE: A COMPARISON AT 24 MONTHS OF 2 CLINICAL TRIALS OF THE GIMEMA-CML WP
A. Poerio, G. Rosti, M. Amabile, I. Iacobucci, S. Soverini, S. Colarossi, A. Gnani, E. Ottaviani, C. Terragna, T. Grafone, S. Luatti, F. Castagnetti, F. Pane, G. Saglio, M. Baccarani, G. Martinelli (Inst.of Hematology "Serŕgnoli", Bologna, Italy)
 
0167 HOMOHARRINGTONINE IS ASSOCIATED WITH A HIGH PROPORTION OF HEMATOLOGIC RESPONSE IN CML PATIENTS WITH HEMATOLOGIC FAILURE TO IMATINIB
P.R. Rousselot, A.S. De Sarrazin, J.M.C. Cayuela, O.M. Maarek, M.P.G. Gaub, F.M. Maloisel (Hôpital Mignot, Le Chesnay, France)
 
0168 ACETYLOME AND PHOSPHOPROTEOME MODIFICATIONS OF IMATINIB SENSITIVE AND RESISTANT CML CELLS AFTER SHORT CHAIN FATTY ACID HISTONE DEACETYLASE INHIBITOR TREATMENT
V. Santini, R. Pastorelli, G. Ferrari, A. Gozzini, D. Tombaccini (University of Florence, Firenze, Italy)
 
0169 IMATINIB THERAPY FOR CHRONIC MYELOID LEUKEMIA PATIENTS WHO RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A MOLECULAR ANALYSIS
F.P. Palandri, M. Amabile, G. Bandini, F. Benedetti, M. Usala, E. Angelucci, M. Tiribelli, R. Fanin, G. Rosti, G. Martinelli, M. Baccarani (University of Bologna, Bologna, Italy)
 
0170 INFLUENCE OF CYP3A4 ACTIVITY ON IMATINIB RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
H. Gréen, K. Skoglund, F. Rommel, L. Bertilsson, K. Lotfi (Linköping University, Linköping, Sweden)
 
0171 IMATINIB 400 MG IN LOW SOKAL RISK CML PATIENTS: EARLY RESULTS OF AN OBSERVATIONAL, MULTICENTRIC TRIAL OF THE GIMEMA CML WP
G. Rosti, F. Castagnetti, I. Iacobucci, N. Testoni, M. Breccia, F. Palandri, G. Specchia, B. Martino, S. Luatti, A. Capucci, A. Poerio, R. Bassan, F. Pane, G. Saglio, G. Martinelli, M. Baccarani (University of Bologna, Bologna, Italy)
 
0172 IMATINB AND AGING: PRELIMINARY RESULTS OF A SUBANALYSIS WITHIN 3 TRIALS OF THE GIMEMA CML WP
F. Castagnetti, G. Rosti, I. Iacobucci, N. Testoni, M. Amabile, E. Usala, D. Russo, E. Orlandi, S. Soverini, E. Montefusco, G. Rege Cambrin, S. Rupoli, G. Martinelli, F. Pane, G. Saglio, M. Baccarani (University of Bologna, Bologna, Italy)
 
0173 BCR-ABL REDUCES CCN3 EXPRESSION THEREBY EVADING NEGATIVE GROWTH REGULATION
L. McCallum, S. Price, W. Lu, N. Planque, B. Perbal, A.D. Whetton, A.E. Irvine (Queen's University Belfast, Belfast, United Kingdom)
 
0174 THE PERSISTENCE OF P190 BCR-ABL TRANSCRIPTS IS ASSOCIATED WITH LOWER PROBABILITY OF MOLECULAR RESPONSE TO IMATINIB IN EARLY AND LATE CHRONIC PHASE CML PATIENTS
A. Ibatici, A. Garuti, S. Pozzi, G. Cirmena, F. Bertolotti, M. Miglino, N. Sessarego, R. Varaldo, N. Colombo, M. Podesta, M. Gobbi, M. Sessarego, F. Patrone, F. Frassoni (Ospedale San Martino, Genova, Italy)
 
0175 IMPACT OF BCR/ABL GENE EXPRESSION ON THE PROLIFERATIVE RATE OF DIFFERENT SUBPOPULATIONS OF HEMATOPOIETIC CELLS IN CHRONIC MYELOID LEUKEMIA
D. Primo, J. Flores, S. Quijano, M.L. Sanchez, M.E. Sarasquete, J. Del Pino-Montes, P.I. Gaarder, M. Gonzalez, A. Orfao (Centro de Investigación del Cáncer, Salamanca, Spain)
 
0176 SURVIVIN AND CIAP-1 GENE EXPRESSION IS LINKED TO CHRONIC MYELOID LEUKEMIA PROGRESSION AND POOR RESPONSE TO IMATINIB
F.A. Castro, J.F. Jacysyn, A.G. Ulbrich, P.R. Tobo, L.R. Lopes, D.L.C. Alves, M.A. Zanichelli, M.D. Colassantti, D. Camanho, C.A. Moreira-Filho, N. Hamerschlak, G.P. Amarante-Mendes (FCFRP-USP, Ribeirăo Preto, Brazil)
 
0177 ABL KINASE DOMAIN MUTATIONS ARE IMPORTANT MECHANISMS OF RESISTANCE IN ASIAN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKAEMIA
T.H. Chuah, Y.T. Goh, L.H. Lee, M. Koh, L.P. Koh, Y. Loh, R. Yiu, L.C. Lim, G.F. How, O. Otheris, J. Tan (Singapore General Hospital, Singapore, Singapore)
 
0178 INCREASED ANGIOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: CLINICAL AND MORPHOLOGICAL ANALYSIS
A. Zhelyazkova, L. Gercheva, P. Kolova, A. Tonchev, L. Ivanova (Varna University of Medicine, Varna, Bulgaria)
 

NON-HODGKIN’S LYMPHOMA - CLINICAL I

 
0179 A PHASE II, MULTICENTER, SINGLE-AGENT STUDY OF BENDAMUSTINE HCL IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA
A. Forero-Torres, J. Foran, P. Cohen, B.D. Cheson, K.S. Robinson, L. Fayad, A.S. La Casce, A. Bessudo, E.S. Camacho, M.E. Williams, R.H. van der Jagt, J.W. Oliver, J.W. Friedberg (University of Alabama at Birmingham, Birmingham, Al, USA)
 
0180 CLINICAL FEATURES AND PROGNOSTIC ASSESSMENT OF NODAL MARGINAL ZONE B-CELL LYMPHOMA, A RARE DISEASE WITH FOLLICULAR-LIKE BEHAVIOUR
L. Arcaini, M. Paulli, E. Boveri, A. Rossi, M. Spina, F. Passamonti, S. Burcheri, M. Montanari, A. Gallamini, L. Uziel, C. Crugnola, C. Pascutto, E. Morra, M. Lazzarino (IRCCS Policlinico San Matteo, Pavia, Italy)
 
0181 PRELIMINARY EVALUATION OF EFFICACY AND TOXICITY OF TWO DOSES SCHEDULES OF BORTEZOMIB PLUS R-CHOP REGIMEN IN FRONT-LINE B LYMPHOMA PATIENTS
F. Remy, V. Ribrag, N. Mounier, C. Haioun, G. Salles, J.B. Golfier, C. Ferme, J. Briere, M. Ertault, P. Brice, C. Gisselbrecht (Hôpital Saint-Louis, Paris, France)
 
0182 CLINICAL FEATURES AND TREATMENT OUTCOMES OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
W.S. Kim, B.B. Park, B.Y. Ryoo, Y.H. Ko, C.W. Suh, J.R. Huh, Y.H. Park, S.S. Lee, S.M. Bang, H.C. Kwon, H.J. Kim, K.W. Park, J.H. Kim, J.H. Kang, K.H. Kim, K.C. Park, E.K. Cho (Samsung Medical Center, Seoul, South-Korea)
 
0183 AUTOIMMUNE DISEASES IN PATIENTS WITH MALT-LYMPHOMA: CHARACTERISTICS AND CLINICAL COURSE
S. Wöhrer, M. Troch, B. Streubl, J. Zwerina, C.C. Zielinski, A. Chott, M. Raderer (Medical University of Vienna, Vienna, Austria)
 
0184 RITUXIMAB-M/VACOP-B COMBINED WITH RADIOTHERAPY IN PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA (PMLBCL): A PROSPECTIVE ITALIAN INTERGROUP PHASE II STUDY
M. Martelli, V. Stefoni, P. Cabras, S. Cortellazzo, E. Brusamolino, A. Levis, E. Gallo, A. De Vivo, F. Natalino, E. Finolezzi, A. Di Rocco, R. Foŕ, P.L. Zinzani (University "La Sapienza", Roma, Italy)
 
0185 ASSOCIATION OF REDUCED RELATIVE DOSE INTENSITY AND SURVIVAL IN LYMPHOMA PATIENTS RECEIVING CHOP-21 CHEMOTHERAPY
R. Pettengell, M. Schwenkglenks, D. Bron, P. Johnson, A. Van Hoof, B. Hancock, R. De Bock, A. Pagliuca, Z. Berneman, R. Thomas, A. Ferrant, M. Joyner, M. Dauwe, G. Verhoef, P. Hoskin, A. Bosly (St. George's Hospital, London, United Kingdom)
 
0186 THE EMERGING ROLE OF FDG PET/CT IN THE PRIMARY STAGING OF LYMPHOMA
J. Trotman, M. Fulham, M. Gibson, A. Mohamed, I. Cunningham, G. Young (Concord Hospital, Sydney, Australia)
 
0187 BORTEZOMIB PLUS RITUXIMAB IN PATIENTS WITH INDOLENT NONHODGKINS LYMPHOMA (NHL): A PHASE 2 STUDY
A. Goy, S. De Vos, S. Dakhil, P. McLaughlin, M. Saleh, R. Belt, C. Flowers, M. Knapp, L. Hart, D. Patel-Donnelly, M. Glenn, S. Gregory, C. Holladay, A. Boral, T. Zhang (Hackensack University Medical Center, Hackensack, USA)
 
0188 CONSOLIDATION OF CHEMOTHERAPY RESPONSE IN MANTLE CELL LYMPHOMA (MCL) PATIENTS WITH 90Y-IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY (RIT)
W.J. Jurczak, M.S. Szostek, A.G. Giza, D.K. Krochmalczyk, J.W. Wegrzyn, A.H. Hubalewska-Dydejczyk, A.S. Sowa-Staszczak, A.H. Hellmann, W.K. Knopinska-Posluszny, B.Z. Zdziarska, S.K. Krycz- Krzemien, L.P. Poplawska, A.S. Skotnicki (CMUJ, Kopernika, Poland)
 
0189 MT103 (ANTI-CD19 X ANTI-CD3 BITE) INDUCES B CELL DEPLETION, CLEARANCE OF BONE MARROW INFILTRATION AND CLINICAL RESPONSES IN HEAVILY PRETREATED NHL PATIENTS: FIRST DATA FROM DOSE-ESCALATION STUDY MT103-104
R. Bargou, P. Kufer, P. Kirchinger, R. Noppeney, M. Schuler, A. Viardot, K. Weigang-Köhler, F. Zettl, M. Libicher, G. Riethmüller, R. Lutterbüse, M. Klinger, C. Reinhardt, P. Bäuerle (Medizinische Klinik II, Würzburg, Germany)
 
0190 PKC-BETA II EXPRESSION HAS PROGNOSTIC IMPACT IN NODAL DIFFUSE LARGE B-CELL LYMPHOMA
R.S. Schaffel (Federal University of Rio de Janeiro, Rio De Janeiro, Brazil)
 
0191 CIGARETTE SMOKING AND ALCOHOL CONSUMPTION AS DETERMINANTS OF SURVIVAL IN NON-HODGKIN'S LYMPHOMA: A POPULATION-BASED STUDY
T. Battaglioli, G. Gorini, A. Seniori Costantini, P. Crosigani, L. Miligi, O. Nanni, S. Stagnaro, R. Tumino, P. Vineis (IRCCS Maggiore Hospital, Milan, Italy)
 
0192 IBRITUMOMAB TIUXETAN COMBINED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH CHEMOREFRACTORY AGGRESSIVE NON-HODGKIN'S LYMPHOMA
A. Shimoni, T. Zwass, Y. Oksman, I. Hardan, N. Shem-Tov, R. Yerushalmi, A. Avigdor, I. Ben-Bassat, A. Nagler (Chaim Sheba Medical Center, Tel-hashomer, Israel)
 
0193 CENTRAL NERVOUS SYSTEM INVOLVEMENT IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA. INCIDENCE AND CLINICAL CHARACTERISTICS
M. Arnan, E. Gonzalez-Barca, E. Domingo-Domenech, A. Oliveira, E. Pina, J. Petit, J. Sarra, M. Encuentra, A. Fernandez de Sevilla (Institut Catala d'Oncologia, L'hospitalet De Llobregat, Spain)
 
0194 CLINICAL FEATURES OF THE WESTERN AND ASIAN FORMS OF INTRAVASCULAR LYMPHOMA (IVL) VARIES ACCORDING TO THE PRESENCE OF HEMOPHAGOCYTIC SYNDROME (HPS) AND NOT TO THE GEOGRAPHICAL AREA
A.J.M. Ferreri, G.P. Dognini, E. Campo, E. Zucca, M. Martelli, A. De Renzo, C. Doglioni, M. Ferracci, C. Montalban, A. Tedeschi, A. Pavlovsky, A. Morgan, L. Uziel, S. Ascani, U. Gianelli, C. Patriarca, F. Facchetti, L. Mazzucchelli, F. Cavalli, M. Ponzoni (San Raffaele Scientific Institute, Milan, Italy)
 
0195 A PHASE II STUDY OF CYCLOPHOSPHAMIDE, VINCRISTINE, NON-PEGYLATED LIPOSOMAL DOXORUBICIN, AND PREDNISONE PLUS RITUXIMAB (RCOMP) IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
M. Federico, M.D. Caballero, E. Thiel, S. Bologna, M.J.S. Dyer, S. Luminari (Universitŕ di Modena e Reggio Emilia, Modena, Italy)
 
0196 INDUCTION WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB FOLLOWED BY RITUXIMAB MAINTENANCE IS A HIGHLY EFFECTIVE FRONT-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA: RESULTS FROM A COOPERATIVE SPANISH TRIAL
J.F. Tomas, C. Montalban, J. Martinez, A. Fernandez de Sevilla, J. Paz, M. Canales, J. Diaz-Mediavilla, P. Sanchez-Godoy, M.D. Caballero, J. Peńalver, E. Prieto, A. Salar, C. Burgaleta, J.A. Queizan, A. Sanchez Salinas, J. de la Serna (MD Anderson International Espańa, Madrid, Spain)
 
0197 INTENSIVE CHEMOTHERAPY (HIGH-DOSE CHOP/ESHAP REGIMEN) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) IN PREVIOUSLY UNTREATED PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL)
S. Mercadal Vilchez, A. López-Guillermo, M. Camós, E. Montserrat, B. Xicoy, J.M. Ribera, L. Lourdes, C. Pedro, C. Estany, J. Briones, R. Martino (H.Clinic, Barcelona, Spain)
 
0198 THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY MAY CHANGE PROGNOSTIC FACTORS, INCLUDING TUMOR BCL-2 EXPRESSION, IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
L. Arenillas, A. Lopez-Guillermo, L. Colomo, A. Martinez-Pozo, F. Bosch, S. Mercadal, J. Carreras, O. Balaguer, N. Villamor, O. Salamero, J. Esteve, E. Campo, E. Montserrat (Hospital Clinic, Barcelona, Spain)
 

NON-HODGKIN’S LYMPHOMA - CLINICAL II

 
0199 CLINICAL OUTCOME OF LOW GRADE NON HODGKIN'S LYMPHOMA PATIENTS WITH BONE MARROW INVOLVEMENT DETECTED BY FLOW CYTOMETRY ALONE
M. Lishner, N. Gronich, J. Radnay, H. Shapiro, Y. Manor, M. Lahav (Meir Medical Center, Kfar Saba, Israel)
 
0200 CHOP (DOXORUBICIN) CHEMOTHERAPY IS SUPERIOR TO CNOP (MITOXANTRONE) IN THE TREATMENT OF PATIENTS WITH AGGRESSIVE NON-HODGKIN LYMPHOMA (REVIEW)
M. Björkholm, T. Andersson, A. Ahlbom, E. Ösby (Karolinska University Hospital, Stockholm, Sweden)
 
0201 EARLY-MID TREATMENT C-REACTIVE PROTEIN (CRP) LEVELS PREDICT TIME TO DISEASE PROGRESSION OR RELAPSE AS WELL AS OVERALL SURVIVAL IN AGGRESSIVE NON-HODGKIN'S LYMPHOMA
Y. Herishanu, C. Perry, U. Metzer, L. Gibpstein, S. Trestman, O. Goor, A. Polliack, E. Napartek (Tel-Aviv Sourasky Medical Center, Tel-aviv, Israel)
 
0202 BEAC OR BEAM CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA PATIENTS: COMPARATIVE ANALYSIS ON EFFICACY AND TOXICITY
C. Suh, J.E. Koo, S. Kim, Y.H. Cho, Y.K. Kang, J. Huh (Asan Medical Center, Seoul, South-Korea)
 
0203 RAPID INFUSION OF RITUXIMAB WITH OR WITHOUT STEROID CONTAINING CHEMOTHERAPY. ONE YEAR EXPERIENCE IN A SINGLE CENTRE
A. Salar, D. Casao, M. Cervera, C. Pedro, E. Gimeno, E. Abella, A. Alvarez- Larrán, M. Calafell, C. Besses (Hospital del Mar, Barcelona, Spain)
 
0204 RITUXIMAB PLUS CLADRIBINE OR CLADRIBINE AND CYCLOPHOSPHAMIDE IN HEAVILY PRETREATED PATIENTS WITH INDOLENT LYMPHOPROLIFERATIVE DISORDERS
T.R. Robak, P. Smolewski, A. Szmigielska-Kaplon, B. Cebula, J.Z. Blonski, K. Chojnowski (Medical University of Lodz, Lodz, Poland)
 
0205 A RETROSPECTIVE STUDY TO ASSESS RELATIVE DOSE INTENSITIES IN PATIENTS WITH LYMPHOMA IN CENTRAL EUROPEAN COUNTRIES
M. Trnen ´y, S. Fekete, J. Walewski, M. Ladicka, G. Kreuzbauer, T. Skacel (Charles University General Hospital, Prague, Czech Republic)
 
0206 COMPARISON BETWEEN 2-DEOXY-2-[18F]FLUORO-D-GLUCOSE POSITRON EMISSION (FDG-PET) AND COMPUTER TOMOGRAPHY (CT) FOR STAGING OF PATIENTS WITH HODGKIN'S LYMPHOMA (HL)
L. Rigacci, F. Merli, A. Castagnoli, A. Versari, L. Nassi, T. Chisesi, A. Gallamini, A. Biggi, U. Vitolo, R. Sancetta, P. Pregno, F. Salvi, A.M. Scattolin, A. Levis, A. Bosi (Azienda Ospedaliera Universitaria, Florence, Italy)
 
0207 MARKED ACTIVITY OF BORTEZOMIB, RITUXIMAB, AND DEXAMETHASON (BORID) IN HEAVILY PRETREATED PATIENTS WITH MANTLE CELL LYMP
J. Drach, H. Kaufmann, O. Pichelmayer, V. Sagaster, S. Seidl, A. Chott, C. Zielinski, M. Raderer (Medical University Vienna, Vienna, Austria)
 
0208 CLINICAL AND CYTOGENETIC CHARACTERISTICS OF HIGH-GRADE NONHODGKIN LYMPHOMA (HGNHL) WITH A COMBINATION OF T(14;18) TRANSLOCATION AND C-MYC REARRANGEMENT: A VERY AGGRESSIVE ENTITY WITH A DISMAL PROGNOSIS.
C.T. Touzeau, N.M. Morineau, H.A.L. Avet-Loiseau, R.G. Garand, P.T. Talmand, A.M. Moreau, T.G. Gastinne, N.M. Milpied, P.M. Moreau, J.L.H. Harousseau, S.L.G. Le Gouill (CHU Nantes, Nantes, France)
 
0209 TRANSPLANT REGIMENS FOR HIGH-RISK MANTLE CELL LYMPHOMA: THE EFFECT OF INCORPORATING IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY ON RELAPSE RATE
A.K. Krishnan, A.R. Raubitschek, S.F. Forman, H.F. Fung, A.M. Molina, D.Y. Yamauchi, P.F. Falk, R.S. Spielberger, L.P. Popplewell, R.R. Rodriguez, P.P. Parker, W.C. Chow, R.N. Nakamura, AN Nademanee (City of Hope National Cancer Center, Duarte, USA)
 
0210 GASTRECTOMY PLUS CHEMOTHERAPY VS. CHEMOTHERAPY ALONE IN GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA OF EARLY STAGE
D. Mihou, P. Konstantinidou, D. Markala, Fr. Patakiouta, N. Constantinou ("Theagenion" Cancer Center, Thessaloniki, Greece)
 
0211 PREDICTORS OF SURVIVAL IN ELDERLY PATIENTS WITH AGGRESSIVE LYMPHOMA. A LONG-TERM FOLLOW-UP OF A RANDOMISED TRIAL
S.Y. Kristinsson, E. Ösby, H. Hagberg, S. Kvaloy, L. Teerenhovi, H. Anderson, H. Holte, E. Cavallin-Stahl, J. Myhre, A. Ost, H. Pertovaara, B. Nilsson, M. Björkholm (Karolinska University Hospital, Solna, Sweden)
 
0212 UPDATE REPORT ON 78 PATIENTS WITH POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS FOLLOWED BY A SINGLE CENTER
E. Ravelli, V. Mancini, G. Muti, P. Oreste, M. Nichelatti, E. Morra (Niguarda Ca' Granda Hospital, Milan, Italy)
 
0213 RISK OF SECOND CANCER IN NON-GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF MALT: A POPULATION-BASED STUDY FROM NORTHERN ITALY
S. Burcheri, L. Arcaini, A. Rossi, C. Pascutto, F. Passamonti, M. Paulli, E. Orlandi, F. Montanari, M. Buelli, P. Viero, M. Lucioni, E. Rumi, A. Algarotti, S. Cortelazzo, M. Lazzarino (IRCCS Policlinico San Matteo, Pavia, Italy)
 
0214 ACHIEVEMENT OF MOLECULAR REMISSION AFTER FIRST LINE TREATMENT PROLONGS SURVIVAL IN FOLLICULAR LYMPHOMA PATIENTS
V.P. Prochazka, Z. Kubová, T. Papajík, R. Plach?, Z. Pikalová, L. Raida, L. Kucerová, K. Indrák, RoĎmanová (Teaching Hospital, Olomouc, Czech Republic)
 
0215 CLINICO-BIOLOGICAL CHARACTERISTICS OF PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA AND HEPATITIS C VIRUS INFECTION
H. Ionita, M. Iordache, I. Ionita, D. Calamar-Popovici, M. Ionita, D. Oros, C. Ionita (UMF Victor Babes, Timisoara, Romania)
 
0216 RITUXIMAB IN INDUCTION TREATMENT AND IN HIGH DOSE CHEMOTHERAPY (HDC) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE THERAPY IN STAGE III-IV DIFFUSE LARGE B-CELL LYMPHOMA AT POOR PROGNOSIS
U. Vitolo, G. Rossi, M.G. Cabras, A.M. Liberati, A. Chiappella, E. Pavone, E. Angelucci, B. Botto, M. Ceccarelli, S. Cortelazzo, R. Freilone, E. Pogliani, D. Rota Scalabrini, F. Salvi, A. Tucci, E. Gallo (ASO S. Giovanni Battista, Torino, Italy)
 
0217 EFFECTS OF PRE-TRANSPLANTATION TREATMENT WITH RITUXIMAB ON OUTCOMES OF AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA
P.O. Obrtlikova, B. Vackova, R. Pytlik, H. Krejcova, P. Klener, M. Trneny (Charles University General Hospital, Prague 2, Czech Republic)
 
0218 COMPARATIVE ANALYSIS OF TREATMENT OUTCOMES WITH CHOP REGIMEN, ETOPOSIDE PLUS CORTICOSTEROID AND PREDNISOLONE IN ADULT PATIENTS WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: BASED ON UNDERLYING DISEASES
H.-J. Shin, J.S. Chung, Y.J. Choi, G.J. Cho, H.-J. Kim, Y.-K. Kim, D.-H. Yang, S.K. Sohn, J.G. Kim, Y.D. Joo, W.S. Lee (Pusan National University Hospital, Busan, South-Korea)
 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES I

 
0219 PP2500 MRNA, A SPLICE VARIANT OF THE MULTIPLE ANKIRIN REPEAT SINGLE KH DOMAIN (MASK), IS HIGHLY EXPRESSED IN PLASMA CELLS OF MULTIPLE MYELOMA
A.S.S.D. Duarte, M.M. Ortega, F.F. Costa, C.S.P Lima, S.T.O. Saad (Hemocentro- State University of Campinas, Campinas, Brazil)
 
0220 A PHASE II STUDY OF THALIDOMIDE, DEXAMETHASONE AND PEGYLATED LYPOSOMAL DOXORUBICIN (THADD) FOR UNTREATED PATIENTS WITH MULTIPLE MYELOMA AGED OVER 65 YEARS
M.O. Offidani, L.C. Corvatta, M.M. Marconi, C.P. Polloni, M.N.P. Piersantelli, G.V. Visani, F.A. Alesiani, M.B. Brunori, C.M. Bigazzi, M.C. Catarini, M.B. Burattini, R.C. Centurioni, L.M. Morbidoni, A.P. Poloni, P.L. Leoni (Clinica di Ematologia, Ancona, Italy)
 
0221 MONOKINE-INDUCED BY INTERFERON-GAMMA (MIG) SERUM LEVELS ARE A MARKER OF DISEASE LOAD AND CORRELATE WITH PROGNOSIS IN MULTIPLE MYELOMA
M. Schreder, G. Koch, D. Heintel, K. Strasser-Weippl, U. Jäger, H. Ludwig, N. Zojer (Wilhelminenspital, Vienna, Austria)
 
0222 VAD-DOXIL VS.VAD-DOXIL PLUS THALIDOMIDE AS INITIAL TREATMENT IN MYELOMA PATIENTS: INTERIM ANALYSIS OF A MULTICENTER RANDOMIZED TRIAL OF THE GREEK MYELOMA STUDY GROUP
K. Zervas, D. Mihou, I. Katodritou, A. Pouli, C.H. Mitsouli, A. Anagnostopoulos, S. Delibasi, M.C. Kyrtsonis, N. Anagnostopoulos, E. Terpos, P. Zikos, A. Maniatis, M.A. Dimopoulos ("Theagenion" Cancer Center, Thessaloniki, Greece)
 
0223 THE COMBINATION OF BORTEZOMIB, MELPHALAN, DEXAMETHASONE AND INTERMITTENT THALIDOMIDE (VMDT) IS AN EFFECTIVE REGIMEN FOR RELAPSED/REFRACTORY MYELOMA AND REDUCES SERUM LEVELS OF RANKL, MIP-1 ALPHA AND ANGIOGENIC CYTOKINES
E. Terpos, A. Anagnostopoulos, E. Kastritis, D. Christoulas, A. Zomas, C. Poziopoulos, N. Anagnostopoulos, K. Tsionos, M.A. Dimopoulos (251 General Airforce Hospital, Athens, Greece)
 
0224 BORTEZOMIB DEMONSTRATES SUPERIOR SURVIVAL COMPARED WITH HIGH DOSE DEXAMETHASONE AND HIGHER RESPONSE RATES AFTER EXTENDED FOLLOW-UP IN THE APEX TRIAL IN RELAPSED MULTIPLE MYELOMA
P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J.L. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. san Miguel, J. Blade, M. Boccadoro, J. Cavenagh, K. Anderson (Dana-Farber Cancer Institute, Boston, USA)
 
0225 SIMPLE, BUT SIGNIFICANT FACTORS FOR SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION IN 181 MULTIPLE MYELOMA PATIENTS: A SINGLE CENTRE EXPERIENCE
M. Krejci, R. Hajek, A. Svobodnik, A. Krivanova, Z. Adam, L. Pour, J. Vorlicek (Faculty Hospital Brno, Brno, Czech Republic)
 
0226 IDENTIFICATION OF NOVEL GENE EXPRESSION SUBGROUPS IN MULTIPLE MYELOMA USING UNSUPERVISED CLUSTER ANALYSIS
E. Kamst, P. Sonneveld (ErasmusMC, Rotterdam, The Netherlands)
 
0227 EFFICACY OF SINGLE-AGENT BORTEZOMIB VERSUS THALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW
- Prince, M. Adena, D. Kingsford Smith, J. Hertel (Peter MacCallum Cancer Centre, Melbourne, Australia)
 
0228 BORTEZOMIB IN RELAPSED MULTIPLE MYELOMA: RESPONSE RATES AND DURATION OF RESPONSE ARE INDEPENDENT OF CHROMOSOME 13Q
J. Drach, E. Küenburg, V. Sagaster, N. Zojer, J. Ackermann, H. Kaufmann, V. Odelga, C. Zielinski, R. Wieser, H. Ludwig (Medical University Vienna, Vienna, Austria)
 
0229 INTEGRATIVE GENOMIC ANALYSIS OF MULTIPLE MYELOMA PATIENTS WITH 13Q DELETION SUGGESTS A ROLE OF CHROMOSOMAL ABERRATIONS IN THE TRANSCRIPTIONAL FINGERPRINT
L. Agnelli, A. Callegaro, G. Poretti, S. Fabris, D. Verdelli, I. Kwee, L. Baldini, F. Morabito, A. Zanella, G. Lambertenghi-Deliliers, F. Bertoni, S. Bicciato, L. Lombardi, A. Neri (Fondazione IRCCS Ospedale Policlinico, Milano, Italy)
 
0230 EFFICACY AND SAFETY OF MELPHALAN/ARSENIC TRIOXIDE/ASCORBIC ACID COMBINATION THERAPY (MAC) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE, MULTICENTER, PHASE II, SINGLE-ARM STUDY
R. Berenson, R. Boccia, D. Siegel, M. Bozdech, A. Bessudo, E. Stadtmauer, J.T. Pomeroy, R. Steis, M. Flam, J. Lutzky, S. Jilani, J. Volk, T. Lindgren, R. Moss, R. Patel, H.S. Yeh (Inst. for Myeloma & Bone Cancer Research, West Hollywood, California, United States of America)
 
0231 INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) IS OVEREXPRESSED IN MULTIPLE MYELOMA PLASMA CELLS (PC) AND REGULATES THE EXPRESSION OF THE IGF-1 RECEPTOR
M.R. Renzulli, C. Terragna, N. Testoni, C. Nicci, C. Taccioli, T. Grafone, P. Tosi, E. Zamagni, P. Tacchetti, G. Perrone, M. Toccafondi, G. Martinelli, M. Baccarani, M. Cavo (Institute of Hematology, Bologna, Italy)
 
0232 AUTOIMMUNITY IS ASSOCIATED WITH BETTER SURVIVAL IN MULTIPLE MYELOMA
O. Landgren, R.M. Pfeiffer, D. Baris, G. Gridley, L. Mellemkjaer, K. Hemminki, L.R. Goldin, N.E. Caporaso (National Cancer Institute, NIH, Bethesda, Maryland, USA)
 
0233 BORTEZOMIB AND HIGH DOSE MELPHALAN: A NEW CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA
D. Roussel, C. Danho, A. Huynh, L. Ysebaert, C. Recher, F. Huguet, C. Nouvel, G. Laurent, M. Attal (CHU Purpan, Toulouse, France)
 
0234 ENOXAPARIN OR ASPIRIN FOR THE PREVENTION OF RECURRENT THROMBOEMBOLISM IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH MELPHALAN AND PREDNISONE PLUS THALIDOMIDE OR LENALIDOMIDE
A. Palumbo, C. Rus, F. Cavallo, A. Bertola, M.T. Petrucci, A.M. Liberati, P. Musto, F. Pisani, S. Morandi, J. Zeldis, F. Rodeghiero, M. Boccadoro (Divisione di Ematologia Univ. Torino, Torino, Italy)
 
0235 INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE (MVTD) AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA
P. Musto, I. Avonto, P.R. Scalzulli, B. Bruno, A. Falcone, M.T. Ambrosini, S. Bringhen, F. Gay, C. Rus, F. Cavallo, P. Falco, M. Massaia, M. Boccadoro, A. Palumbo (Italian Myeloma Network, Gimema, Italy)
 
0236 THALIDOMIDE-DEXAMETHASONE VS THALIDOMIDEDEXAMETHASONE AND PEGYLATED LIPOSOMAL DOXORUBICIN: A CASE-MATCHED STUDY IN PATIENTS WITH ADVANCED MULTIPLE MYELOMA
M.O. Massimo, S.B. Bringhen, L.C. Corvatta, M.M. Marconi, P.F. Falco, I.A. Avonto, G.V. Visani, F.A. Alesiani, M.B. Brunori, M. Ruggieri, M.C. Catarini, M.N.P. Piersantelli, C.P. Polloni, P.L. Leoni, A.P. Palumbo (Clinica di Ematologia, Ancona, Italy)
 
0237 DYSFUNCTION OF TOLL-LIKE RECEPTORS: A POSSIBLE IMPLICATION IN THE PATHOGENESIS OF IMMUNODEFICIENCY IN MULTIPLE MYELOMA
E. Andreakos, M.A. Dimopoulos, K. Tsionos, C. Xirakia, A. Anagnostopoulos, E. Katodritou, K. Zervas, P. Sideras, E. Terpos (Academy of Athens, Athens, Greece)
 
0238 CLINICOPATHOLOGICAL CORRELATES OF PLASMA CELLS CD56 (NCAM) EXPRESSION IN MULTIPLE MYELOMA
M. Kraj, U. Sokolowska, J. Kopec- Szlezak, R. Poglod, B. Kruk, J. Wozniak, K. Owczarska (Institute of Haematology and Blood Trans, Warsaw, Poland)
 

MYELOMA AND OTHER MONOCLONAL GAMMOPATHIES I

 
0239 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN MULTIPLE MYELOMA, SOLITARY PLASMOCYTOMA AND MONOCLONAL GAMMAPATHY OF UNKNOWN SIGNIFICANCE
Z.A. Adam (University Hospital, Brno, Czech Republic)
 
0240 TREATMENT WITH BENDAMUSTINE, THALIDOMIDE AND PREDNISOLONE (BPT) IN ADVANCED MYELOMA PATIENTS: RESULTS OF A PHASE I CLINICAL TRIAL
W. Pönisch, M. Rozanski, F.A. Hoffmann, T.H. Boldt, A. Schwarzer, U. Ruffert, J. Uhlig, R. Rohrberg, U. Kreibich, D. Niederwieser (University of Leipzig, Leipzig, Germany)
 
0241 CANTHARIDIN, A DERIVATIVE OFBLISTER BEATLES INDUCES APOPTOSIS IN MULTIPLE MYELOMA CELLS VIA INHIBITION OF IL-6-INDUCIBLE STAT3 PATHWAY: NEW AGENT FOR SIGNAL TRANSDUCTION THERAPY OF MULTIPLE MYELOMA
M.S. SAGAWA, T.N. Nakazato, Y.I. Ikeda, M.K. Kizaki (KEIO University School of Medicine, Tokyo, Japan)
 
0242 CITRULLINE CONCENTRATION AFTER HIGH-DOSE MELPHALAN IN AUTOLOGOUS HSCT RECIPIENTS
N.M.A Blijlevens, J.P. Donnelly, A.V.M.B. Schattenberg, T.J.M. de Witte (UMC St. Radboud, Nijmegen, The Netherlands)
 
0243 PLASMA CELL PROPIDIUM IODIDE (PC-PI/CD138) AND ANNEXIN V (PCAI/ CD138) INDICES IN MULTIPLE MYELOMA AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE - EARLY PREDICTORS OF TRANSFORMATION?
J.M. Minarik, V.S. Scudla, M.O. Ordeltova, J.B. Bacovsky, M.Z. Zemanova, T.P. Pika (3rd Department of Internal Medicine, Olomouc, Czech Republic)
 
0244 EPIDEMIOLOGY OF ANEMIA IN 720 PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM EUROPEAN ANAEMIA SURVEY (ECAS)
H. Ludwig, P. Gascón, S. Van Belle, - For ECAS Investigators (Wilhelminenspital, Vienna, Austria)
 
0245 A PHASE I/II STUDY OF ARSENIC TRIOXIDE, BORTEZOMIB, AND ASCORBIC ACID IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
R. Berenson, J. Matous, D. Ferretti, R.A. Swift, R. Mapes, B. Morrison, H.S. Yeh (Inst. for Myeloma & Bone Cancer Research, West Hollywood, California, USA)
 
0246 PREVALENCE OF RAS GENE MUTATIONS IN THE CONTEXT OF A MOLECULAR CLASSIFICATION OF MULTIPLE MYELOMA
D. Intini, L. Agnelli, S. Fabris, G. Ciceri, L. Nobili, L. Baldini, F. Morabito, S. Bicciato, L. Lombardi, A. Zanella, G. Lambertenghi-Deliliers, A. Neri (Fondazione IRCCS Ospedale Policlinico, Milano, Italy)
 
0247 PERSONAL HISTORY OF REPEATED PNEUMONIA IS ASSOCIATED WITH INCREASED RISK OF MULTIPLE MYELOMA
O. Landgren, J. Rapkin, L. Mellemkjaer, G. Gridley, L.R. Goldin, E.A. Engels (National Cancer Institute, NIH, Bethesda, Maryland, USA)
 
0248 MINIMAL RESIDUAL DISEASE CAN BE DETECTED IN ALMOST ALL MULTIPLE MYELOMA PATIENTS IN REMISSION USING A COMBINED APPROACH OF FIVE-COLOUR FLOW CYTOMETRY AND INTERPHASE FISH ON SUBSEQUENTLY SORTED PLASMA CELLS
S. Franke, B. Maes, M. Berten, G. Bries, V. Madoe, K. Magerman, A. Mewis, P. Declercq, R. Cartuyvels, V. Peeters, K. Hensen, J.L. Rummens (Virga Jesse Hospital, Hasselt, Belgium)
 
0249 BORTEZOMIB TRANSIENTLY INHIBITS OSTEOCLAST ACTIVITY IN CELL CULTURE CONDITIONS MIMICKING IN VIVO INTERMITTENT TREATMENT
P. Boissy, T. Plesner, J.M. Delaisse (Vejle Hospital, Vejle, Denmark)
 
0250 COMBINATION THERAPY EFFECTS OF LENALIDOMIDE IN FGFR3 MULTIPLE MYELOMA CELL LINES
A. Gandhi, J. Kang, L. Capone, P. Schafer, W. Sherman, D. Stirling (Celgene Corporation, Summit, USA)
 
0251 A NOVEL IN VIVO ANIMAL MODEL FOR HUMAN MULTIPLE MYELOMA BASED ON BIOLUMINESCENCE IMAGING OF TUMOR CELL GROWTH
H. Rozemuller, I. Koggel, R. Spaapen, A. Hagenbeek, A.C.M. Martens (University Medical Center, Utrecht, The Netherlands)
 
0252 RELATIVE QUANTIFICATION OF TUMOR ASSOCIATED ANTIGENS MAGE-A1 AND MAGE-A3 IN MULTIPLE MYELOMA
J.V. Vigasova, J. Kadlecova, R. Spesna, R. Gaiyllova, M. Penka, J. Michalek, R. Hajek (Faculty Hospital Brno, Brno- Bohunice, Czech Republic)
 
0253 POST RELAPSE AND OVERALL SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA THAT PROGRESSED AFTER DECEMBER 1998
I.H. Hardan, A.S. Shimoni, A.K. Kneller, A.A. Avigdor, M.B. Bercowicz, I.D. Davidiwits, N.S. Shem-Tov, M.L. Leiba, R.Y. Yerushalmi, I.B. Ben-Bassat, A.N. Nagler (Sheba Medical enter, Tel-hashomer, Israel)
 
0254 OPG/ RANKL SYSTEM IN MULTIPLE MYELOMA
V.S Goranova-Marinova, S.E. Goranov, P.I. Pavlov, A.D. Bojadzhieva (University Hospital "Sv.Georgi", Plovdiv, Bulgaria)
 
0255 SAFETY AND EFFICACY OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DAILY ONCOLOGY PRACTICE
H. Freimann, A. Calderoni, P. Cornu, R.A. Olie (KSSW Kantonales Spital Sursee- Wolhusen, Sursee, Switzerland)
 
0256 MULTIPLE MYELOMA (MM) IN BRAZIL: CLINICAL AND DEMOGRAPHIC FEATURES AND THE UTILITY OF ISS IN 1,017 PATIENTS, MOSTLY WITH ADVANCED DISEASE
V. Hungria, A. Maiolino, G. Martinez, A.C.C. Choair, E.O.M. Coelho, L. Rocha, R.F.M. Nunes, L.M.R. Silla, L. Oliveira, R.M.D. Faria, R. Pasquini, S.M.M. Magalhăes, C.A. Souza, J.V. Pinto Neto, L. Barreto (Santa Casa de Sao Paulo, Sao Paulo, Brazil)
 
0257 EVALUATION OF 4 STAGING SYSTEMS IN 470 MYELOMA PATIENTS: VALIDATION OF THE SUPERIOR PROGNOSTIC SIGNIFICANCE OF THE INTERNATIONAL STAGING SYSTEM
D. Mihou, I. Katodritou, D. Markala, K. Zervas ("Theagenion" Cancer Center, Thessaloniki, Greece)
 
0258 OSTEONECROSIS OF THE JAW IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH BISPHOSPHONATES: A SINGLE CENTER EXPERIENCE
E. Verrou, A. Banti, E. Terpos, D. Mihou, Z. Teleioudis, D. Krikelis, K. Vahtsevanos, K. Zervas ("Theagenion" Cancer Center, Thessaloniki, Greece)
 

CLL AND RELATED DISORDERS - CLINICAL / EXPERIMENTAL I

 
0259 DETECTION OF RISK-IDENTIFYING MARKERS AND ADDITIONAL ABERRATIONS BY MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) IN CHRONIC LYMPHATIC LEUKEMIA
A. Buijs, P.J. Krijtenburg, E. Meijer (UMC Utrecht, Utrecht, The Netherlands)
 
0260 QUANTITATIVE GENE EXPRESSION ANALYSIS OF SURROGATE MARKERS FOR GENETIC RISK GROUPS AND SURVIVAL IN CLL
D. Kienle, A. Benner, A. Kröber, D. Winkler, P. Lichter, R. Dalla-Favera, H. Döhner, S. Stilgenbauer (University of Ulm, Ulm, Germany)
 
0261 DISTINCT EXPRESSION LEVELS OF NOXA IN PERIPHERAL VERSUS LYMPH NODE CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE LINKED WITH SURVIVAL CAPACITY
E. Eldering, L.A. Smit, D.Y.H. Hallaert, R. Spijker, B. de Goeij, M.H.J. van Oers, C.J. van Noesel (Academical Medical Center, Amsterdam, The Netherlands)
 
0262 SIGNIFICANT CORRELATION BETWEEN OBJECTIVE RESPONSES AND EXPOSURE TO HUMAX-CD20 IN CHRONIC LYMPHOCYTIC LEUKEMIA
B. Coiffier, H. Tilly, L.M. Pedersen, T. Plesner, H. Frederiksen, M.H.J. van Oers, J. Woolridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. Walewski, M.F. Flensburg, J. Petersen, T. Robak (Centre Hospitalier Lyon Sud, Pierre-benite Cedex, France)
 
0263 CD40 LIGATION SENSITIZES P53 DYSFUNCTIONAL CLL CELLS TO CHEMOTHERAPY INDUCED APOPTOSIS VIA THE P73 PATHWAY
A.P. Kater, F. Dicker, C.E. Prada, J.E. Castro, T.J. Kipps (Academic Medical Center, Amsterdam, The Netherlands)
 
0264 RHAMM/CD168 IS A NOVEL LEUKEMIA ASSOCIATED ANTIGEN WITH PROGNOSTIC VALUE FOR PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
K.G. Giannopoulos, A. Kröber, A. Dmoszynska, J. Rolinski, H. Döhner, S. Stilgenbauer, M. Schmitt (Medical University of Lublin, Lublin, Poland)
 
0265 PARTHENOLIDE INDUCES REACTIVE OXYGEN SPECIES AND SELECTIVE APOPTOSIS OF B-CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS VIA A P53 INDEPENDENT PATHWAY
J. Steele, G. Prentice, A.V. Hoffbrand, B. Mehta, K. Ganeshaguru, R.G. Wickremasinghe (Royal Free and UCL Medical School, London, United Kingdom)
 
0266 SMALL MOLECULE PAN-BCL2 FAMILY INHIBITOR OBATOCLAX (GX15- 070): FINAL RESULTS OF A SINGLE AGENT PHASE I TRIAL IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
S. O'Brien, D. Claxton, M. Crump, S. Faderl, T. Kipps, M. Keating, B. Cheson (MD Anderson Cancer Center, Houston, USA)
 
0267 COMPARISON OF EX VIVO DRUG SENSITIVITY BY TRAC ASSAY AND PATIENT RESPONSE IN THE UK LRF CLL4 TRIAL
A.G. Bosanquet, S.L. Raper, J. Durant, S.M. Scadding, S.M. Richards, D. Catovsky (Bath Cancer Research, Bath, United Kingdom)
 
0268 INTRACELLULAR CYTOKINE EXPRESSION BY B AND T CELLS DIFFERS IN ZAP-70 POSITIVE AND ZAP-70 NEGATIVE B-CLL PATIENTS
M. Podhorecka, A. Bojarska-Junak, J. Rolinski, A. Dmoszynska (Medical University of Lublin, Lublin, Poland)
 
0269 ACCUMULATION OF T-CELLS WITH EXTREMELY SHORT TELOMERES IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)
A. Röth, J. Dürig, H. Himmelreich, R. Siebert, S. Bug, U. Dührsen, P. Lansdorp, G. Baerlocher (University Hospital Essen, Essen, Germany)
 
0270 INTRACLONAL DIVERSIFICATION OF IMMUNOGLOBULIN LIGHT CHAIN VARIABLE REGION GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA
E. Kostareli, K. Stamatopoulos, A. Daglis, C. Belessi, A. Hadzidimitriou, N. Stavroyianni, T. Smilevska, V. Tachynopoulou, M. Gounari, F. Marantidou, N. Laoutaris, A. Anagnostopoulos, A. Fassas, A. Kouvatsi (Aristotle University, Biology School, Thessaloniki, Greece)
 
0271 QUANTITATION OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA USING LNA-MODIFIED FLUORESCENTLY LABELED PROBES AND REAL-TIME PCR TECHNOLOGY
P.S. Pekova, S.L. Saudkova, S.L. Smolej, K.T. Kozak (Hospital Na Homolce, Prague 5, Czech Republic)
 
0272 ADOPTIVE IMMUNOTHERAPY OF B-CELL MALIGNANCIES WITH A TRIFUNCTIONAL, BISPECIFIC ANTIBODY (ANTI-CD3 X ANTICD20) AND ALLOGENEIC DONOR LYMPHOCYTE TRANSFUSION
R. Buhmann, M. Stanglmaier, B. Simoes, T. Yang, P. Ruf, H. Lindhofer, H.J. Kolb (GSF, Munich, Germany)
 
0273 TELOMERE LENGTH IS A PROGNOSTIC FACTOR STRONGER THAN VH-MUTATIONAL STATUS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL)
I. Ricca, R. Francese, A. Rocci, D. Drandi, C. Lobetti Bodoni, M. Compagno, E. Genuardi, M. Rosace, M. Astolfi, P. Omedč, A. Gallamini, C. Marinone, L. Bergui, M. Boccadoro, C. Tarella, M. Ladetto (University of Turin, Torino, Italy)
 
0274 HIGHLY SENSITIVE DETECTION OF MINIMAL RESIDUAL DISEASE IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA BY INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION ON FLOW SORTED CELLS
K. Hensen, S. Franke, H. Jongen, V. Peeters, P. Declercq, K. Magerman, A. Mewis, R. Cartuyvels, J.L. Rummens, B. Maes (Virga Jesse Hospital, Hasselt, Belgium)
 
0275 MRD KINETIC AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CAN PREDICT INDIVIDUAL TIME TO RELAPSE AND IS ASSOCIATED WITH CLINICAL OUTCOME AND IGVH MUTATIONAL STATUS
M. Ritgen, S. Boettcher, S. Stilgenbauer, H. Dohner, M. Bruggemann, C. Pott, T. Raff, N. Schmitz, R. Busch, M. Hallek, M. Kneba, P. Dreger (Universitätsklinikum Schleswig-Holstein, Kiel, Germany)
 
0276 MDR-1, BUT NOT MDR-3 GENE EXPRESSION, IS ASSOCIATED WITH UNMUTATED IGVH GENES AND POOR PROGNOSIS CHROMOSOMAL ABERRATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
H.D. Alexander, C. Matthews, M.A. Catherwood, A. Larkin, M. Clynes, T.C.M. Morris (Belfast City Hospital Trust, Belfast, Northern Ireland)
 
0277 ANTILEUKEMIC ACTIVITY OF LENALIDOMIDE (L) {REVLIMID} IN PATIENTS (PTS) WITH RELAPSED (REL) OR REFRACTORY (REF) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
A. Chanan-Khan, K. Miller, L. Musial, S. Padmanabhan, D. Lawrence, Z. Bernstein, K. Takeshita, D. Spaner, C. Byrne, C. Crystal, M. Czuczman (Roswell Park Cancer Institute, Buffalo, USA)
 
0278 ZAP-70 EXPRESSION IN B-CLL IS ASSOCIATED WITH INCREASED RISK OF AUTOIMMUNE CYTOPENIAS
R. Zanotti, A. Ambrosetti, A. Andreoli, M. Chilosi, M. Lestani, A. Remo, F. Frattini, A. Andreini, G. Pizzolo (Section of Hematology, Verona, Italy)
 
0279 IN-VITRO TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS WITH FLUDARABINE, ETOPOSIDE AND ALEMTUZUMAB (CAMPATH-1H) LEADS TO SPECIFIC MECHANISMS AND RATES OF CELL DEATH IN DIFFERENT GENETIC SUBGROUPS
D. Winkler, C. Schneider, D. Nitsch, A. Habermann, H. Döhner, St. Stilgenbauer (Uniklinik Ulm, Ulm, Germany)
 
0280 ANALYSIS OF EXPRESSED AND NON-EXPRESSED IMMUNOGLOBULIN LAMBDA LOCUS REARRANGEMENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
E. Tsakou, A. Daglis, C. Belessi, K. Stamatopoulos, A. Hadzidimitriou, N. Stavroyianni, C. Vadikolia, E. Kalagiakou, G. Kokkini, G. Paterakis, C. Georgopoulos, R. Saloum, A. Anagnostopoulos, A. Fassas, N. Laoutaris (Nikea General Hospital, Piraeus, Greece)
 
0281 ACTIVATION-INDUCED CYTIDINE DEAMINASE EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA
F. Marantidou, C. Belessi, K. Stamatopoulos, V. Douka, E. Kalagiakou, I. Athanasiadou, E. Manioudaki, K. Valianatou, A. Tsompanakou, G. Paterakis, A. Saetta, P. Korkolopoulou, N. Anagnostopoulos, N. Laoutaris, E. Patsouris (Athens University School of Medicine, Athens, Greece)
 

HODGKIN’S LYMPHOMA - CLINICAL TRIALS

 
0282 RESULTS OF ABVD AND HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN ADVANCED STAGE, HIV-RELATED HODGKIN'S LYMPHOMA (HL)
B. Xicoy, J.M. Ribera, B. Mahillo, J. Berenguer, P. Miralles, R. Rubio, M.E. Valencia, E. Abella, A. Gaya, A. Sureda, J. Vergas, M.L. Montes, J. Lacruz, M. Morgades, H. Esteban (Gesida and Gelcab Groups, Badalona, Spain)
 
0283 HODGKINS LYMPHOMA IN ADOLESCENTS - RESULTS FROM THE GERMAN HODGKIN STUDY GROUP
H. Bredenfeld, A. Engert, V. Diehl, E. Gilman, B. Pfistner (University Hospital Cologne, Cologne, Germany)
 
0284 INC-EU PROSPECTIVE OBSERVATIONAL EUROPEAN NEUTROPENIA STUDY: PRELIMINARY HODGKIN AND NON-HODGKIN LYMPHOMA RESULTS
R. Pettengell, A. Bosly, T.D. Szucs, C. Jackisch, R. Leonard, R. Paridaens, M. Constenla, M. Schwenkglenks (St. George's Hospital, London, United Kingdom)
 
0285 IFOSFAMIDE, VP16 AND OXALIPLATINE (IVOX) CHEMOTHERAPY FOR PATIENTS IN FIRST PROGRESSION OF HODGKIN LYMPHOMA (HL) AFTER ABVD CHEMOTHERAPY, A SINGLE CENTER PROSPECTIVE STUDY OF 21 PATIENTS
P. Brice, N. Mounier, M. Ertault, P. Franchi, J. Briere, P. Colin, N. Parquet, G. Sergent, C. Gisselbrecht (Hôpital Saint-Louis, Paris Cedex 10, France)
 
0286 LYMPHOCYTE-PREDOMINANT HODGKIN'S LYMPHOMA IN CHILDREN: THERAPEUTIC ABSTENTION AFTER INITIAL LYMPH NODE RESECTION IN STAGE I PATIENTS. A REPORT FROM THE SOCIETE FRANCAISE DES CANCERS DE L'ENFANT (SFCE)
S. Gorde, O. Oberlin, T. Leblanc, Y. Perel, A. Robert, D. Plantaz, C. Schmitt, Y. Bertrand, H. Pacquement, C. Edan, A. Lambilliotte, P. Lutz, G. Michel, F. Demeocq, C. Behar, G. Vaudre, S. Fasola, A. Baruchel, G. Leverger, J. Landman-Parker (Hopital Trousseau, Paris, France)
 
0287 ADMINISTRATION OF FULL DOSE DOXORUBICIN, BLEOMYCIN, VINBLASTINE, DACARBAZINE (ABVD) CHEMOTHERAPY IRRESPECTIVE OF GRANULOCYTE COUNT IN PATIENTS WITH HODGKIN LYMPHOMA (HL): MAINTENANCE OF DOSE INTENSITY WITHOUT GROWTH FACTORS
E. Boleti, R. Cathomas, T.R. Geldart, P.W.M. Johnson, G. Mead (Southampton University Hospital, Southampton, United Kingdom)
 
0288 THE IMPACT OF THE SOCIOECONOMIC STATUS IN PATIENTS WITH HODGKIN'S DISEASE IN BRAZIL
I. Biasoli, A. Soares, A. Scheliga, R.R. Luiz, S. Romano, M.A. Costa, J.C. Morais, N. Spector (Federal University of Rio de Janeiro, Rio De Janeiro, Brazil)
 
0289 POLYMORPHISMS OF GLUTATHIONE S-TRANSFERASE MU1 (GSTM1) AND TETHA 1 (GSTT1) GENES IN HODGKIN'S LYMPHOMA RISK
C. Lima, G. Lourenço, R. Kameo, I. Néri, F. Costa, I. Lorand-Metze (State University of Campinas, Campinas, Brazil)
 
0290 LACE (LOMUSTINE, ARA-C, CYCLOPHOSPHAMIDE, ETOPOSIDE) CONDITIONED AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: TREATMENT OUTCOME AND RISK FACTOR ANALYSIS IN 67 PATIENTS FROM A SINGLE CENTRE.
J.B. Perz, C. Giles, R. Szydlo, D. O`Shea, J. Sanz, A. Chaidos, S. Wagner, D. MacDonald, E. Kanfer (University Heidelberg, Heidelberg, Germany)
 
0291 67GA-SPET HAS A ROLE IN PREDICTING DISEASE FREE SURVIVAL (DFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH PRIMARY MEDIASTINAL LYMPHOMA AND HODGKIN LYMPHOMA WITH MEDIASTINAL INVOLVEMENT
A.M. Liberati, I. Palumbo, G. Desantis, B. Palumbo, L. Falchi, P. Cerroni, D. Siepi, V. Capparella, A. Lugini, M. Cianciulli (Medicina Interna e Scienze Oncologiche, Perugia, Italy)
 
0292 AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PATIENTS WITH REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: CLINICAL OUTCOME OF 61 PATIENTS FROM A SINGLE INSTITUTION
C. Martínez, O. Salamero, L. Arenillas, M. Rovira, A. Urbano-Ispízua, F. Fernández-Avilés, E. Carreras, E. Montserrat (Institute of Hematology and Oncology, Barcelona, Spain)
 
0293 COMPARISON BETWEEN FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY AND STANDARD RESTAGING IN AGGRESSIVE LYMPHOMA PATIENTS TREATED WITH HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANPLANTATION
P. Pregno, E. Pelosi, A. Chiappella, G. Limerutti, G. Benevolo, B. Botto, L. Orsucci, D. Penna, S. Scaglia, E. Gallo, G. Bisi, U. Vitolo (ASO S. Giovanni Battista, Torino, Italy)
 

ALLOGENEIC STEM CELL TRANSPLANTATION I

 
0294 CLINICAL RESISTANCE TO PRETRANSPLANT IMATINIB THERAPY IS AN ADVERSE PROGNOSTIC FACTOR FOR THE OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION IN CML
M. Weisser, M. Schleuning, C. Schoch, R. Schwerdtfeger, H.J. Kolb (Klinikum Grosshadern, Munich, Germany)
 
0295 IL-12, MYELOID DENDRITIC CELLS AND THE TH1 MODEL IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
M. Mohty, B. Gaugler, C. Faucher, S. Furst, D. Olive, D. Blaise (Institut Paoli-Calmettes, Marseille, France)
 
0296 MOLECULAR REMISSION IN FOLLICULAR LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION CORRELATES WITH A BETTER DISEASE FREE SURVIVAL
L.F. Farina, A. Dodero, M. Carrabba, C. Carniti, E. Zorzan, F. Ciceri, A. Rambaldi, F. Patriarca, A. Locasciulli, A. Santoro, A. Olivieri, P. Corradini (Istituto Nazionale dei Tumori, Milan, Milano, Italy)
 
0297 IMPACT OF T-CELL CHIMERISM AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
M. Mohty, O. Avinens, C. Faucher, S. Furst, H. De Lavallade, J. El Cheikh, P. Viens, J.A. Gastaut, D. Blaise, J.F. Eliaou (Institut Paoli- Calmettes, Marseille, France)
 
0298 B-CELL CONCENTRATION IN THE APHERETIC PRODUCT PREDICTS ACUTE GRAFT-VERSUS-HOST-DISEASE AND TREATMENT- RELATED MORTALITY OF ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
G.F. Torelli, A.P. Iori, S. De Propriis, C. Fazio, F. Milano, B. Lucarelli, R. Cerretti, L. Cerilli, L. Malandruccolo, E. Iannella, A. Guarini, R. Foŕ (University "La Sapienza", Roma, Italy)
 
0299 ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTS (HSCT) FOR PATIENTS WITH RELAPSED ACUTE LEUKEMIA : LONG TERM OUTCOME
A. Bacigalupo, T. Lamparelli, F. Gualandi, D. Occhini, S. Bregante, A.M. Raiola, A. Ibatici, C. di Grazia, A. Dominietto, G. Piaggio, M. Podestŕ, B. Bruno, A. Lombardi, F. Frassoni, C. Viscoli, N. Sacchi, M.T. Van Lint, D. Vicente (Ospedale San Martino, Genova, Italy)
 
0300 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) WITH EXTRACORPOREAL PHOTOPHERESIS (ECP)
P. Bavaro, P. Accorsi, E. Di Bartolomeo, P. Di Carlo, A. Iacone, P. Olioso, G. Papalinetti, S. Santarone, P. Di Bartolomeo (Bone Marrow Transplant Center, Pescara, Italy)
 
0301 IMPACT OF DISPARITIES AT SINGLE OR MULTIPLE HLA LOCI ON OUTCOME AFTER UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) FOR ADULTS WITH HEMATOLOGIC MALIGNANCIES
S. Cantero, N. Puig, J.I. Lorenzo, G. Martin, J. Martinez, I. Jarque, C. Jimenez, D. Planelles, J. Moscardo, M.A. Sanz, G. Sanz (Hospital La Fe, Valencia, Spain)
 
0302 CORTICOSTEROIDS FOR PREVENTING GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER MYELOABLATIVE STEM CELL TRANSPLANTATION: A COMPREHENSIVE METAANALYSIS
S. Quellmann, J. Bohlius, K. Huebel, G. Schwarzer, A. Engert (University of Cologne, Cologne, Germany)
 
0303 REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: DOES THE CONDITIONING MATTER? - A RETROSPECTIVE STUDY OF THE SFGM-TC ON 61 PATIENTS
L.T. Terriou, Z. Chir, H. Esperou, N. Milpied, J.M. Boiron, J.P. Vernant, N. Gratecos, M. Michallet, J.P. Jouet, I. Yakoub-Agha (Hopital Ci.Huriez, Lille, France)
 
0304 PROGENITOR CELLS ARE TRAPPED IN FILTERS USED FOR MARROW HARVEST: RECOVERING CELLS FROM MARROW FILTERS REDUCES GRAFT VS HOST DISEASE AND TRANSPLANT MORTALITY
D. Vicente, M. Podestŕ, A. Pitto, S. Pozzi, S. Lucchetti, T. Lamparelli, E. Tedone, A. Ibatici, O. Figari, F. Frassoni, M.T. Van Lint, G. Piaggio, N. Sacchi, A. Bacigalupo (Ospedale San Martino, Genova, Italy)
 
0305 EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR TREATMENT OF FASCIITIS IN CHRONIC GRAFT - VERSUS - HOST DISEASE (CGVHD) : A PILOT STUDY
M. Stadler, A. Achenbach, J. Funke, S. Buchholz, H. Kamal, M. Eder, B. Hertenstein, A. Ganser, R. Stadler (Hannover Medical School, Hannover, Germany)
 
0306 REDUCED INTENSITY CONDITIONING (RIC) IN ALLO-BMT FOR RESISTANT-RELAPSED LYMPHOMAS
P. Mazza, G. Palazzo, M.R. Specchia, G. Console, A.M. Carella, G. Pisapia, P. Iacopino (Ospedale "S.G. Moscati", Taranto, Italy)
 
0307 FLUDARABINE BASED REDUCED INTENSITY CONDITIONING (RIC) FOR ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH NON-MALIGNANT HEMATOLOGICAL DISORDERS
B. George, V. Mathews, A. Viswabandya, A. Srivastava, M. Chandy (Christian Medical College, Vellore, Vellore, Tamilnadu, India)
 
0308 SAFETY AND EFFICACY OF BORTEZOMIB IN RELAPSED MULTIPLE MYELOMA FOLLOWING REDUCED INTENSITY/NONMYELOABLATIVE CONDITIONINGS AND ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
L. Giaccone, R. Sorasio, F. Patriarca, D. Mattei, P. Corradini, V. Montefusco, J. Peccatori, R. Fanin, F. Carnevale-Schianca, S. Guidi, M.T. Petrucci, G. Milone, M. Rotta, B. Bruno, M. Boccadoro (University Torino, Torino, Italy)
 
0309 CYTOKINES AND T-CELL SUBSETS CHANGE IN PATIENTS HAVING GRAFT-VERSUS-HOST DISEASE
S.P. Yeh, C.F. Chiu, W.J. Lo, C.L. Lin, Y.M. Liao, C.C. Lee (China Medical University Hospital, Taichung, Taiwan)
 
0310 INCREASED INCIDENCE OF CYTOMEGALOVIRUS RETINITIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
A. Xhaard, M. Robin, C. Scieux, R. Peffault De Latour, S. Deplus, A. Devergie, V. Rocha, E. Gluckman, P. Ribaud, G. Socie (Hôpital Saint- Louis, Paris, France)
 
0311 STEM CELL DONORS RECRUITED FROM RURAL POPULATIONS HAVE A POTENTIAL TO INCREASE POLYMORPHISM OF UNRELATED DONOR REGISTRIES
J. Nowak, R. Mika-Witkowska, M. Polak, M. Zajko, M. Rogatko-Koros, E. Graczyk-Pol, A. Lange (Institute of Haematology and Blood Trans, Warsaw, Poland)
 
0312 POOR PROGNOSIS FOR PATIENTS AFTER MYELO- AND NONMYELOABLATIVE CONDITIONING THERAPY FOLLOWED BY ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION ADMITTED TO INTENSIVE CARE UNIT
F. Neumann, O. Lobitz, R. Fenk, T. Graef, I. Bruns, A. Peters, T. Zeus, M. Kelm, A. Hünerlitürkoglu, U. Germing, R. Haas, G. Kobbe (Heinrich-Heine University Duesseldorf, Duesseldorf, Germany)
 
0313 HEMATOPOIETIC STEM CELL (HSC) RECRUITMENT HAS AN INFLUENCE ON TRANSPLANT OUTCOME AFTER REDUCED INTENSITY ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT): A STUDY OF THE SOCIETE FRANCAISE DE GREFFE DE MOELLE OSSEUSE ET DE THERAPIE CELLULAIRE (SFGM-TC) REGISTRY
T. Prebet, Q.H. Le, J.M. Boiron, D. Blaise, A. Huyhn, I. Yakoub Agha, H. Esperou, M. Michallet (Institut Paoli Calmettes, Marseille, France)
 
0314 TACROLIMUS AND MYCOPHENOLATE MOFETIL FOR GVHD PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED INTENSITY CONDITIONING
G. Kobbe, T. Graef, R. Fenk, F. Zohren, L. Ruf, M. Kondakci, H. Pape, A. Bernhardt, R. Kronenwett, R. Haas (UKD, Duesseldorf, Germany)
 
0315 COMPARATIVE OUTCOMES OF FLUDARABINE-BASED NONABLATIVE AND ABLATIVE CONDITIONING FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
I. Kim, B. Kim, S. Kim, Y. Kim, S. Bang, S. Yoon, J.S. Lee, S. Park, B.K. Kim (Seoul National University Hospital, Seoul, South-Korea)
 
0316 IMMUNO HAEMATOLOGICAL RECONSTITUTION AFTER T-CELL-DEPLETED HLA-HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR THALASSEMIA
A. Isgrň, B. Erer, P. Sodani, P. Polchi, M. Marziali, W. Leti, C. Gramiccioni, W. De Santis, M. Campagna, G. Del Giudice, M.C. Sirianni, F. Aiuti, G. Lucarelli (Mediterranean Institute of Hematology, Rome, Italy)
 
0317 HIGH EFFICACY OF PULSE CYCLOPHOSPHAMIDE IN CORTICOSTEROID- REFRACTORY LIVER GRAFT-VERSUS-HOST DISEASE
M. Krejci, J. Mayer, M. Doubek, Y. Brychtova, J. Kamelander, J. Vorlicek (Faculty Hospital Brno, Brno, Czech Republic)
 

APOPTOSIS / TRANSCRIPTIONAL CONTROL / SIGNALLING

 
0318 HALOFUGINONE, INHIBITOR OF TRANSFORMING GROWTH FACTOR (TGF) B INDUCES APOPTOSIS AND CELL CYCLE ARREST OF MULTIPLE MYELOMA CELLS IN VITRO AND IMPROVES HIND LIMB PARALYSIS IN THE 5T2 MM MOUSE MODEL IN VIVO
J. Medvedev, K. Halevi-Tobias, M. Leiba, M. Ohana, L. Drucker, M. Lishner, S. Yarkoni, A. Nagler (Collgard Biopharmacuticals Ltd, Petach Tikva, Israel)
 
0319 DOWNREGULATION OF RXRALPHA EXPRESSION IS ESSENTIAL FOR THE DIFFERENTIATION AND PROLIFERATION OF NEUTROPHIL GRANULOCYTES
S. Taschner, C. Kösters, W. Ellmeier, H. Strobl (Medical University Vienna, Vienna, Austria)
 
0320 TRAIL-R3 EXPRESSION ON MYELOID LEUKEMIC BLASTS IS RELATED TO SHORTENED OVERALL SURVIVAL
M.E.D. Chamuleau, L. van Dreunen, A. Zevenbergen, G.J. Ossenkoppele, A.A. van de Loosdrecht (VUMC Medical Center, Amsterdam, The Netherlands)
 
0321 HTLV-1 PROPELS UNTRANSFORMED CD4+ LYMPHOCYTES INTO THE CELL CYCLE WHILE PROTECTING CD8+ CELLS FROM DEATH, AND ESTABLISHES A CD4+ RESTRICTED PRELEUKEMIC PHENOTYPE
D. Sibon, A.S. Gabet, M. Zandecki, C. Pinatel, J. Thete, M.H. Delfau-Larue, S. Rabaaoui, A. Gessain, O. Gout, S. Jacobson, F. Mortreux, E. Wattel (Centre Léon Bérard, Lyon, France)
 
0322 OLIGONUCLEOTIDE TARGETING OF THE BCL11B LOCUS CONTROL REGION REVEALS DISTINCT LEUKEMOGENIC ZONES AT DNASE-I HYPERSENSITIVE SITES
S. Nagel, M. Scherr, M. Kaufmann, A. Kel, K. Hornischer, H.G. Drexler, R.A.F. MacLeod (DSMZ, Braunschweig, Germany)
 
0323 ABSENCE OF SPRED1, A NEGATIVE REGULATOR OF TYROSINE KINASE ACTIVITY, IN CHRONIC MYELOID LEUKAEMIA PATIENTS
D. Cilloni, F. Messa, E. Bracco, I. Defilippi, S. Carturan, D. Di Giovanni, F. Arruga, V. Rosso, R. Catalano, P. Nicoli, A. Morotti, M. Baccarani, G. Martinelli, G. Saglio (University of Turin, Turin, Italy)
 
0324 ROLE OF ID AND HES PROTEINS IN ACUTE PROMYELOCYTIC LEUKEMIA
J. Nigten, M. Timmermans, S. van Wageningen, G. Nikoloski, T. de Witte, B.A. van der Reijden, J.H. Jansen (Radboud University Medical Centre, Nijmegen, The Netherlands)
 
0325 REGULATION OF AUTOPHAGIC PROGRAMMED CELL DEATH (PCD) BY THE BALANCE BETWEEN CERAMIDE AND SPHINGOSINE-1- PHOSPHATE THROUGH MAMMALIAN TARGET OF RAPAMYCIN (MTOR) IN HUMAN LEUKEMIA HL-60 CELLS
N.D. Domae (Osaka Dental University, Kirakata-city, Japan)
 
0326 THE MACHANISMS UNDERLYING THE CYTOTOXIC EFFECT OF CDK INHIBITOR (ROSCOVITINE) ON LEUKEMIC CELL LINES
H. Song, Z. Hassan (Karolinska Institute, Stockholm, Sweden)
 
0327 THE BIOLOGIC SIGNIFICANCE OF CD40/CD40-LIGAND AND FAS/FAS LIGAND INTERACTIONS ON HAEMOPOIETIC PROGENITOR CELLS
I. Mavroudi, K. Pyrovolaki, G. Eliopoulos, H.A. Papadaki (University of Crete School of Medicine, Heraklion, Greece)
 
0328 METHYLATION-ASSOCIATED TRANSCRIPTIONAL SILENCING OF THE C/EBP ALPHA GENE IN ACUTE MYELOGENOUS LEUKEMIA
E.J. Jost, N. Ň, S. Wilop, J.G. Herman, R. Osieka, O. Galm (UK Aachen, Aachen, Germany)
 
0329 ROLE OF SIGNAL TRANSDUCTION PATHWAYS AND THE MICROENVIRONMENT IN THE EMERGENCE OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA
M.A. van der Pol, W.J. Scholten, B. Moshaver, R. de Boer, N. Feller, G.J. Ossenkoppele, S. Zweegman, G.J. Schuurhuis (VU University Medical Center, Amsterdam, The Netherlands)
 
0330 TRANSIENT POST-TRANSLATIONAL UPREGULATION OF TELOMERASE ACTIVITY DURING MEGAKARYOCYTIC DIFFERENTIATION
M. Nakadake (Tokyo Womens Medical University, Tokyo, Japan)
 
0331 PAX5/TEL CAUSES DOWN MODULATION OF CD19 IN PRE-B CELLS
G. Fazio, A. Biondi, G. Cazzaniga, A. Rolink (Centro Ricerca Tettamanti, Monza (mi), Italy)
 
0332 OVEREXPRESSION OF 14-3-3 SIGMA IS ASSOCIATED WITH TYROSINE KINASE ACTIVITY OF P210 BCR-ABL FUSION PROTEIN OF CHRONIC MYELOID LEUKEMIA
M. Mancini , E. Zuffa, G. Brusa, P. Corrado, E. Barbieri, M.A. Santucci (Istituto di Ematologia Serŕgnoli, Bologna, Italy)
 
0333 THE INVOLVEMENT OF C:18 CERAMIDE AND HUMAN LONGEVITY ASSURANCE GENES IN IMATINIB INDUCED APOPTOSIS
Y.B. Baran, J.B. BIELAWSKI, C.E.S. SENKAL, B.O. Ogretmen, U.G. Gunduz (Middle east Technical University, Ankara, Turkey)
 
0334 SURVIVIN AND BCL2 EXPRESSION IN CD30-POSITIVE LYMPHOPROLIFERATIVE DISORDERS OF THE SKIN COMPARED TO SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMAS: AN IMMUNOHISTOCHEMICAL STUDY OF 28 CASES
G. Goteri, S. Rupoli, D. Stramazzotti, F. Fazioli, A. Tassetti, S. Pulini, D. Morichetti, P. Leoni, L. Lomuzio, G. Fabris (Institute of Pathology, Torrette Di Ancona, Italy)
 
0335 TARGETING IAPS OVERCOMES APOPTOSIS RESISTANCE OF PANCREATIC CARCINOMA CELLS AND SUPPRESSES TUMOR GROWTH AND INVASION IN VIVO
S. Fulda, M. Vogler, K. Duerr, K.M. Debatin (University Children's Hospital, Ulm, Germany)
 
0336 TRAIL RECEPTORS IN B-CLL PATIENTS INDEPENDENTLY OF ZAP 70 EXPRESSION
M. Dourado, A.C. Gonçalves, E. Emília, I. Sousa, A. Paiva, A. Pereira, F. Guedes, A. Teixeira, A.B. Sarmento Ribeiro (Faculty of Medicine of Coimbra, Coimbra, Portugal)
 
0337 P38-MEDIATED ACTIVATION OF CASPASES IN C2-CERAMIDEINDUCED APOPTOSIS OF MOUSE HEMATOPOIETIC CELLS
S. Ota, M. Musashi, N. Toyoshima, K. Kondo, J. Sugita, T. Toubai, N. Kato, J. Tanaka, K. Kimura, M. Imamura, M. Asaka (Hokkaido University, Sapporo, Japan)
 
0338 CERAMIDE GLYCOSYLATION BY GLUCOSYL CERAMIDE SYNTHASE INHIBITS THE APOPTOTIC EFFECT OF IMATINIB ON HUMAN K562 AND MEG-01 CELLS
Y.B. Baran, J.B. Bielawski, C.E.S. Senkal, B.O. Ogretmen, U.G. Gunduz (Middle east Technical University, Ankara, Turkey)
 
0339 NOSCAPINE INDUCES APOPTOSIS THROUGH ACTIVATION OF CASPASES AND MITOCHONDRIAL EVENTS IN P53-NULL MYELOBLASTIC LEUKEMIA CELL LINE K562
B.G. Goliaei, N.H. Heidari, M.M. Mahmoudian, P.R. Rahimi (University of Tehran, Tehran, Iran)
 
0340 ERYTHROID-SPECIFIC TRANSCRIPTIONAL REGULATION OF THE HUMAN PROTOPORPHYRINOGEN OXIDASE GENE IS MEDIATED BY TWO GATA-1 SITES IN EXON 1
K.M.K. de Vooght, R. van Wijk, W.W. van Solinge (University Medical Center Utrecht, Utrecht, The Netherlands)
 
0341 THE NOVEL GENE JUNE-1 IS DIFFERENTIALLY EXPRESSED DURING ERYTHROID DIFFERENTIATION AND IS EXPRESSED IN TUMOUR CELLS
P. Rainey, V.J. Smyth, V.M. Hodges, E. Dunlop, T.R.J. Lappin (Queen's University Belfast, Belfast, United Kingdom)
 
0342 CLINICAL AND PROGNOSTIC SIGNIFICANCE OF P53 GENE MUTATION IN ACUTE LEUKEMIA
M. Awad, Y. Al-Tonbary, O. El-Agrody, S. El-Sharawy, D. El-Ghanam (Mansoura University Faculty of Medicine, Mansoura, Egypt)
 

STEM CELL TRANSPLANTATION - EXPERIMENTAL

 
0343 MATURATION OF NK CELL PHENOTYPE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
S. Giebel, J. Dziaczkowska, T. Czerw, J. Wojnar, I. Nowak, T. Kruzel, M. Krawczyk-Kulis, M. Markiewicz, I. Wylezol, A. Holowiecka-Goral, K. Jagoda, P. Kusnierczyk, J. Holowiecki (Silesian Medical University, Katowice, Poland)
 
0344 CD 3/28 COSTIMULATION INCREASES CHRONIC GRAFT-VERSUS-HOST-INDUCING CAPACITY OF HUMAN T CELLS IN RAG2-/-GAMMAC-/- MICE
R.S. van Rijn, R. Simonetti, A. Hagenbeek, T. Mutis, M. Bonyhadi, G. Storm, A.C.M. Martens, S.B. Ebeling (Jordanlaboratory of Hemato-Oncology, Utrecht, The Netherlands)
 
0345 CD4+CD25+ REGULATORY T CELLS ARE GENERATED AFTER BONE MARROW TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING REGIMENS IN AN ANTIGEN SPECIFIC FASHION
L. Weng, P.J. Dyson, F. Dazzi (Imperial College, London, United Kingdom)
 
0346 IMATINIB IMPAIRS PROLIFERATION AND FUNCTION OF CD8+ T LYMPHOCYTES SPECIFICALLY DIRECTED AGAINST THE LEUKEMIA-ASSOCIATED ANTIGEN RHAMM/CD168
J. Chen, A. Schmitt, B. Chen, M. Ringhoffer, S. Von Harsdorf, J. Greiner, H. Döhner, D. Bunjes, M. Schmitt (University of Ulm, Ulm, Germany)
 
0347 BORTEZOMIB INDUCES APOPTOSIS AND MODIFIES THE MATURATION PATTERN OF DENDRITIC CELLS: ROLE IN THE INDUCTION OF IMMUNOTOLERANCE AFTER ALLOGENEIC TRANSPLANTATION
J.A. Pérez-Simón, I. Sánchez-Abarca Bernal, B. Blanco Durango, S. Tavera, M. Diez-Campelo, M. Alberca, M. Sánchez-Guijo, N. López-Holgado, E. Villarón, C. del Cańizo, J. San Miguel (Hospital Universitario, Salamanca, Spain)
 
0348 STEM CELL FACTOR ENHANCES T-CELL RECOVERY AND THYMOPOIESIS FOLLOWING EXPERIMENTAL BMT
E.J Wils, J.C. Rombouts, E. de Haas, H. Spits, B. Lowenberg, E. Braakman, J.J. Cornelissen (ErasmusMC, Rotterdam, The Netherlands)
 
0349 IS BODY-WEIGHT-BASED CALCULATION OF IV BUSULFAN FIXED DOSE THE APPROPRIATE DOSAGE OF BUSULFAN IN CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
G. Vassal, H. Espérou, J.C. Gentet, F. Doz, D. Valteau-Couanet, B. Neven, C. Galambrun, F. Méchinaud, C. Paillard, H. Zouabi, L. Nguyen, G. Michel (Institut Gustave Roussy, Villejuif, France)
 
0350 TRANSPLANTATION OF HUMAN PERIPHERAL BLOOD CD34- POSITIVE CELLS IN COMBINATION WITH EX VIVO EXPANDED MEGAKARYOCYTES IN NOD/SCID MICE
M.R. Tijssen, P.B. van Hennik, F. di Summa, P.L. Hordijk, J.J. Zwaginga, C.E. van der Schoot, C. Voermans (Sanquin Research, Amsterdam, The Netherlands)
 
0351 THE T CELL RECEPTOR REPERTOIRE USAGE DIFFERS BETWEEN CD4+CD25+ REGULATORY T CELLS AND THEIR CD4+CD25- COUNTERPART AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
C. Fozza, E. Nadal, M. Longinotti, F. Dazzi (Imperial College, London, United Kingdom)
 
0352 THE GRAFT VERSUS HOST DISEASE AND SURVIVAL MIGHT BE DIFFERENT ACCORDING TO ADMINISTRATION ROUTE AND DOSE OF MESENCHYMAL STEM CELL LINE IN MHC MISMATCHED MURINE HEMATOPOIETIC STEM CELL TRANSPLANTATION
P. Jeong, D. Lee, B. Cho, N. Chung, H. Kim, C. Han (The Catholic University of Korea, Inchon, South-Korea)
 
0353 TWO ISOFORMS OF HUMAN FOXP3 POSSESS SIMILAR CAPACITIES TO INDUCE DIFFERENTIATION OF REGULATORY T CELLS FROM CD4+CD25- T CELLS
T. Mutis, L.F. Verdonck, M.I. Aarts-Riemens, M.E. Emmelot (University Medical Center Utrecht, Utrecht, The Netherlands)
 
0354 BODY-WEIGHT-BASED IV BUSULFAN FIXED DOSING AS PART OF BUMEL REGIMEN BEFORE AUTOLOGOUS TRANSPLANTATION IN CHILDREN WITH HIGH RISK SOLID TUMORS: REDUCED TOXICITIES IN THE FRENCH PROSPECTIVE MULTICENTRE STUDY
D. Valteau-Couanet, J.C. Gentet, F. Doz, D. Frappaz, C. Paillard, O. Hartmann, V. Cadic, C. Levrault, H. Zouabi, L. Nguyen, G. Michel, G. Vassal (Institut Gustave Roussy, Villejuif, France)
 
0355 TELOMERE LENGTH OF HAEMATOPOIETIC CELLS FOLLOWING AUTOLOGOUS OR ALLOGENEIC TRANSPLANTATION REFLECTS THAT OF GRAFTED STEM CELLS
I. Ricca, A. Rocci, R. Francese, C. Lobetti Bodoni, M. Compagno, M. Ruella, E. Genuardi, F. Sanavio, M. Carrabba, M. Zanni, D. Caracciolo, M. Boccadoro, M. Ladetto, P. Corradini, C. Tarella (University of Turin, Torino, Italy)
 
0356 PERMANENT TELOMERE LOSS IN MYELOID CELLS FROM LONG-TERM SURVIVORS OF LYMPHOMA PATIENTS TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOGRAFT
A. Rocci, I. Ricca, C. Della Casa, P. Longoni, M. Compagno, R. Francese, C. Lobetti Bodoni, P. Manzini, D. Caracciolo, M. Boccadoro, D. Ferrero, M. Ladetto, C. Carlo-Stella, C. Tarella (University of Turin, Torino, Italy)
 
0357 HIGH DOSE CHEMOTHERAPY (HDCT)+AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MULTIPLE SCLEROSIS (MS) PATIENTS: TREATMENT OUTCOMES AT LONG-TERM FOLLOW-UP
Y. Shevchenko, A. Novik, B. Afanasiev, I. Lisukov, O. Rykavicin, S. Shamanski, T. Ionova, A. Kulagin, O. Malysheva, N. Baziy, V. Melnichenko, D. Fedorenko, I. Vereschagina, A. Kishtovich, Y. Fedotov, G. Gorodokin (Russian Cooper, Moscow, Russian Federation)
 
0358 DAY 15 NATURAL KILLER (NK) CELL RECOVERY PREDICTS PROGRESSION-FREE SURVIVIAL AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN NON-HODGKIN'S LYMPHOMA
M.A. Siddiqui, S.N. Markovic, W.K. Nevala, C.B. Ulh, W.G. Morice, L.F. Porrata (Mayo Clinic Rochester, Rochester, USA)
 
0359 AM3 THERAPY PREVENTS MUCOSITIS IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELLS TRANSPLANTATION
V. Recasens, A. Rubio-Martinez, D. Rubio-Felix, P. Giraldo (Miguel Servet University Hospital, Zaragoza, Spain)
 
0360 INFLUENCE OF THE ADMINISTRATION ORDER OF BUSULFAN AND CYCLOPHOSPHAMIDE ON THE ENGRAFTMENT AND CHIMERISM IN SYNGENEIC STEM CELL TRANSPLANTATION MOUSE MODEL
B. Sadeghi, M. Jansson, Z. Hassan, C. Nilsson, M. Abedi-Valugerdi, M. Hassan (Karolinska Institute, Stockholm, Sweden)
 
0361 HIGH PROPORTIONS OF CD4+CD25+ CELLS IN BLOOD LYMPHOCYTES DETECTED EARLY POST HSCT ASSOCIATE WITH AGVHD AND HERALD ITS SEVERITY
A.L. Lange, D.D. Dlubek, D.D. Drabczak-Skrzypek, A.M. Mlynarczewska (Institute of Immunology, Wroclaw, P
 
0362 SHORTENING OF NEUTROPENIA IN LYMPHOMA PATIENTS AFTER TRANSPLANTATION OF LIN ENRICHED CELLS EXPANDED EX VIVO
M. Klabusay, Z. Koristek, J. Vinklarkova, J. Mayer (University Hospital Brno, Brno, Czech Republic)
 
0363 CONTINUOUS INFUSION IDARUBICIN AND ORAL BUSULPHAN (IBU) AS CONDITIONING FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
F. Ferrara, F. Pollio, M. Celentano, M. De Simone, P. Correale, A. Viola, M. Alberti, G. Mele, S. Palmieri (Cardarelli Hospital, Napoli, Italy)
 
0364 HIGHER DOSE OF CD4+ T CELLS IN THE ALLOGRAFT AND THE OCCURRENCE OF ACUTE GVHD ARE ASSOCIATED WITH IMPAIRED KIRS EARLY RECONSTITUTION AFTER UNMANIPULATED HLA-MISMATCHED/HAPLOIDENTICAL BLOOD AND MARROW TRANSPLANTATION
X. Zhao, J. Wan, X. Huang (Peking University Institute of Hematolog, Beijing, China)
 
0365 EARLY AND LONG-TERM ENGRAFTMENT AFTER AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA PATIENTS
D. Pastore, A. Mestice, P. Carluccio, M. Leo, M. Giannoccaro, M. Casanova, S. Sibilla, G. Spinosa, P. Mongelli, V. Liso, G. Specchia (Hematology, Bari, Italy)
 
0366 MURINE MODEL OF STEM CELL TRANSPLANTATION AND GVHD BASED ON CHEMOTHERAPY CONDITIONING
B. Sadeghi, Z. Hassan, M. Abedi-Valugerdi, M. Hassan (Karolinska Institute, Stockholm, Sweden)
 
0367 IN VIVO LUCIFERASE EXPRESSION OF TRANSDUCED HEMATOPOIETIC STEM CELL POPULATIONS USING THE NON-INVASIVE BIOLUMINESCENT IMAGING
H. Rozemuller, E. van der Spek, L.H. Bogers-Boer, M.C. Zwart, A.C. Bloem, H.C. Lokhorst, A.C.M. Martens (University Medical Center, Utrecht, The Netherlands)
 

INFECTIOUS DISEASES (INCL. SUPPORTIVE CARE)

 
0368 RELATIONSHIP BETWEEN HTLV-1-ASSOCIATED ANTIBODIES, TAXSPECIFIC CYTOTOXIC T LYMPHOCYTES, AND PROVIRAL LOAD AMONG HTLV-1 CARRIERS
M. Akimoto, T. Kozako, T. Sawada, K. Matsushita, K. Uozumi, N. Arima, C. Tei (Kagoshima University Hospital, Kagoshima, Japan)
 
0369 WHAT IS THE VALUE OF THE NECROPSIC STUDY ON CLINICAL HISTORY OF PATIENTS WHO DIED OF MALIGNANT HEMATOLOGIC ILLNESSES?
M.J. Moreno, F.A. Arriba, V.P. Pérez, A.J. Jerez, C.C. Castilla, M.L. Lopez, F.P. Pastor, J.M. Moraleda, VV. Vicente (Hospital Morales Meseguer, Murcia, Spain)
 
0370 CMV INFECTION AND DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. A SINGLE CENTER EXPERIENCE
Y. Floisand, J. Rřislien, B. Fossum Lřland, E. Holter, H. Rollag, L. Brinch (Rikshospitalet National Hospital, Oslo, Norway)
 
0371 AMPLIFICATION OF AN ASPERGILLUS SPP. SPECIFIC REGION OF THE 18S RRNA GENE BY REAL-TIME POLYMERASE CHAIN REACTION ON SERUM SAMPLES AS DIAGNOSTIC TOOL FOR INVASIVE ASPERGILLOSIS IN FEBRILE HEMATOLOGICAL PATIENTS
C. Cattaneo, C. Bottelli, L. Bassani, D Colombrita, E. Borlenghi, M.A. Capucci, A. Caruso, G. Rossi (Spedali Civili, Brescia, Italy) Torino, Italy)
 
0372 INFECTIOUS COMPLICATIONS IN HAEMATOLOGICAL PATIENTS WITH CENTRAL VENOUS CATHETERS: A PROSPECTIVE ANALYSIS OF RISK FACTORS AND ETIOLOGICAL AGENTS
G. Nador, A. Nosari, A. De Gasperi, L. Marbello, M. Nichelatti, A. Corti, V. Mancini, A. Molteni, C. Baratč, F. Ricci, D. Ciapanna, F. Garrone, E. Ravelli, A. Greco, M. Turrini, E. Morra (Niguarda Ca' Granda Hospital, Milan, Italy)
 
0373 RESPIRATORY VIRAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
R. Gilmore, A. Fortune, P.V. Browne, E. Vandenberghe, S.R. McCann, B. Crowley, E. Conneally (St James Hospital., Dublin 8., Ireland)
 
0374 REVERSE SEROCONVERSION OF HEPATITIS B VIRUS (HBV) AFTER ALLOGENEIC OR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
A.M. Mihara, T. Mori, Y. Aisa, T. Nakazato, R. Yamazaki, C.K. Chen, K. Yokoyama, Y. Ikeda, S. Okamoto (Keio Univeristy School of Medicine, Tokyo, Japan)
 
0375 HEPATITIS AND REACTIVATION OF HBV DURING TREATMENT OF DLBCL PATIENTS: AN UNDERESTIMATED EVENT
O. DeHenau, L. Ysebrant, I. Ahmad, M.C. Ngirabacu, J. Bennani, A. Georgala, N. Meuleman, D. Bron (Institut J. Bordet, Brussels, Belgium)
 
0376 ORAL VALGANCICLOVIR IS AN EFFECTIVE PRIMARY PREEMPTIVE THERAPY OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANT (SCT).
A.C. Candoni, R. Mestroni, C. Filě, S. Buttignol, M. Cerno, R. Fanin (University Hospital, Udine, Italy)
 
0377 BAL AS DIAGNOSTIC TOOL IN SEVERE PNEUMONIA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: SINGLE CENTER REPORT ON 16 PATIENTS
A. Manna, S. Cordani, M. Vignali, G. Benini, L. Cadenotti, P. Canessa (ASL5 La Spezia, La Spezia, Italy)
 
0378 SURVIVAL AND DISEASE COMPLICATIONS OF THALASSEMIA MAJOR - 14 YEARS EXPERIENCE AT KING ABDULAZIZ UNIVERSITY HOSPITAL, JEDDAH, KSA
S.K. Al Jaouni (King Abdulaziz University, Jeddah, Saudi Arabia)
 
0379 EFFECTIVENESS OF NONINVASIVE VENTILATION IN TREATMENT OF ACUTE RESPIRATORY FAILURE IN ONCOHEMATOLGICAL PATIENTS
B. Gil, A. López, M.J. Moreno, J.A. Barnes, A. Jerez, V. Perez, M.M. Osma, B. Gil, A. Carrillo (Hospital Morales Meseguer, Murcia, Spain
 
0380 INCIDENCE AND RISK FACTORS OF INVASIVE FUNGAL INFECTIONS (IFI) IN 246 PATIENTS UNDERGOING RELATED OR UNRELATED ALLOGENEIC BONE MARROW TRANSPLANTATION.
A.C. Candoni, S. Lovato, E. Simeone, E. Calistri, S. Buttignol, R. Fanin (University Hospital, Udine, Italy)
 
0381 INVASIVE FUNGAL INFECTIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Y. Floisand, B. Fossum Lřland, J. Rřislien, U. Randen, P. Gaustad, L. Brinch (Rikshospitalet National Hospital, Oslo, Norway)
 
0382 INTENSIFIED ENVIRONMENTAL SURVEILLANCE IN A STEM CELL TRANSPLANTATION WARD DURING CONSTRUCTION WORK
A. Nihtinen, V.J. Anttila, M. Richardson, L. Volin, T. Ruutu (Dept. Med., Helsinki Univ. Central Hosp., Helsinki, Finland)
 
0383 HICKMAN CATHETER-RELATED COMPLICATIONS IN ADULTS WITH HAEMATOLOGICAL/ONCOLOGICAL DISEASES: SINGLE CENTER EXPERIENCE OF 243 DEVICES
A. Jerez, M.J. Lopez, I. Heras, J.M. Felices, F. Bernal, J.M. Moraleda, V. Vicente (University Hospital JM Morales Meseguer, Murcia, Spain)
 
0384 ORAL VALGANCICLOVIR TREATMENT FOR CYTOMEGALOVIRUS DISEASE IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS
M. Palladino, P. Piccioni, L. Laurenti, P. Cattani, P. Chiusolo, G. Reddiconto, S. De Matteis, S. De Vita, L. De Padua, F. Sorŕ, N. Piccirillo, G. Farina, S. Sica, G. Leone (Universitŕ Cattolica del Sacro Cuore, Rome, Italy)
 
0385 ANTIMICROBIAL PROPHYLAXIS AGAINST INFECTIOUS COMPLICATIONS OF AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE II STUDY
C. Suh, O.B. Ko, S. Kim, Y.H. Cho (Asan Medical Center, Seoul, South-Korea)
 
0386 PREDICTIVE FACTORS OF SEPTIC SHOCK AND MORTALITY IN NEUTROPENIC PATIENTS
R. Jeddi, M. Zarrouk, Y. Benabdennebi, K. Kacem, R. Belakhal, L. Aissaoui, H. Benabid, Z. Belhadjali, B. Meddeb (Aziza Othmana Hospital, Tunis, Tunisia)
 
0387 ANALYSIS OF COMPLICATIONS OF CENTRAL VENOUS CATHETERS (CVC) IN ADULT HAEMATOLOGY PATIENTS.
S. Tamiazzo, D. Gioia, A. Bellora, L. Gambarini, M.G. Candeo, B. Allione, F. Salvi, A. Levis (SS Antonio e Biagio Hospital, Alessandria, Italy)
 
0388 VARICELLA-ZOSTER VIRUS INFECTIONS AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION: RELATIONSHIP WITH CD4+ CELL COUNTS
M. Albo, I. Figueroa, C. Ares, C. Poderós, E. Benitez, J. Plaza (Complexo Hospitalario de Vigo, Vigo, Spain)
 
0389 AUDIT OF THE USE OF CT SCANNING AND RISK STRATIFICATION IN THE DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
M.W. Besser, E.J. Gudgin, M.T.G. Gaskarth, N.J. Screaton, A.K. Dixon, J.I.O. Craig, R.E. Marcus (West Suffolk Hospital, Bury St.edmunds, United Kingdom)
 
0390 CLINIC-ANALYTIC PROFILE AND USEFULNESS OF BONE MARROW SMEAR EXAMINATION AND SEROLOGICAL METHODS IN PATIENTS WITH VISCERAL LEISHMANIASIS. EXPERIENCE OF OUR CENTER
E.MŞ. Eva MŞ, E.MŞ. Donato, J. Marco, R. García-Boyero, M. Guinot, C. Mas-Ochoa, A. Escolá, I. García, E. Herrera-De Pablo, M. Más, T. Gozalbo, J. Amela, G. Cańigral (General Hospital of Castellon, Castellón, Spain) United Kingdom)
 

INFECTIOUS DISEASES (INCL. SUPPORTIVE CARE)

 
0391 DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM CAN BE TREATED AT HOME IN PATIENTS WITH CANCER
S. Siragusa, C. Arcara, R. Anastasio, A. Malato, F. Fulfaro, V. Cigna, M. Sciacca, I. Abbene, L. Lo Coco, G. Bajardi, V. Abbadessa, N. Gebbia (University of Palermo, Palermo, Italy)
 
0392 A GLOBAL ASSAY FOR THE ASSESSMENT OF LOW MOLECULAR WEIGHT HEPARINS' ANTITHROMBOTIC ACTIVITY IN VITRO
A. Petropoulou, G. Gerotziafas, M.M. Samama, I. Elalamy (Hotel-Dieu Hospital, Paris, France)
 
0393 RISK OF RECURRENT VENOUS THROMBOEMBOLISM ASSOCIATED WITH PREGNANCY IN WOMEN WITH A HISTORY OF VENOUS THROMBOSIS
A. Gerhardt, R.E. Scharf, R.B. Zotz (Universitätsklinikum Duesseldorf, Duesseldorf, Germany)
 
0394 MAJOR HAEMORRHAGE BEFORE VENOUS THROMBOEMBOLISM: DIFFERENT OUTCOMES DEPENDING ON THE BLEEDING SITE
J.A. Nieto Rodríguez, M.J. Bruscas Alijarde, M.D. Ruiz Ribó, E. Grau Segura, R. Lecumberri, A. Grau Martín, E. Raguer Sanz, R. Guijarro Merino (Hospital Virgen de la Luz, Cuenca, Spain)
 
0395 SUBOPTIMAL DOSES OF LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT OF VENOUS THROMBOEMBOLIC DISEASE
M.J. Bruscas Alijarde, J.A. Nieto Rodríguez, M. Pérez Pinar, M.T. Orue Lecue, I. López Lagunas, P. Román Sánchez, F. López Chuliá, J. Sanchís Cervera (Hospital Virgen de la Luz, Cuenca, Spain)
 
0396 ELEVATED PROTHROMBIN FRAGMENT F1+2 LEVELS DURING PREGNANCY IN WOMEN WITH PREVIOUS VENOUS THROMBOEMBOLISM
A. Gerhardt, S. Marzotko, H.G. Bender, R.E. Scharf, R.B. Zotz (Universitätsklinikum Düsseldorf, Duesseldorf, Germany)
 
0397 RECURRENT FETAL LOSS: PROSPECTIVE EVALUATION OF THE EFFICACY OF THREE DIFFERENT THROMBOPROPHYLAXIS REGIMENS: ASPIRIN VERSUS LOW MOLECULAR WEIGHT HEPARIN VERSUS LOW MOLECULAR WEIGHT HEPARIN PLUS ASPIRIN
A. Chistolini, F. Torelli, A. Giancotti, P. Pignoloni, B. Muto, C. Cosimo, C. Santoro, M.G. Mazzucconi (University La Sapienza Rome, Rome, Italy)
 
0398 THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PREGNANCY AND PUERPERIUM WITH NO ANTITHROMBOTIC PROPHYLAXIS
V. De Stefano, I. Martinelli, E. Rossi, T. Battaglioli, T. Za, P.M. Mannucci, G. Leone (Catholic University, Rome, Italy)
 
0399 A THROMBOELASTOGRAPHIC STUDY IN WHOLE BLOOD EMPLOYING A FIBRIN POLYMERIZATION INHIBITOR (PEFABLOC?) AND AN INHIBITOR OF ACTIN POLYMERIZATION (CYTOCHALASIN D)
A. Petropoulou, G. Gerotziafas, M.M. Samama, T. Chakroun, M. Hatmi, I. Elalamy (Hotel-Dieu Hospital, Paris, France)
 
0400 PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES HAVE A HIGH INCIDENCE OF ANTI-ADAMTS13
S. Austin, A. Lawrie, R. Starke, M. Scully, S.J. Machin, H. Cohen, I. Mackie (University College London, London, United Kingdom)
 
0401 B-VITAMIN SUPPLEMENTATION INCREASES MARKERS OF ENDOTHELIAL FUNCTION IN PATIENTS WITH VENOUS THROMBOEMBOLISM
C.A. Rodrigues, R.C. da Silveira, M.A.E. Noguti, V.M. Morelli, V. D'Almeida, A.A. Garcia, F.H.A. Maffei, D.M. Lourenco (Universidade Federal de Sao Paulo, Sao Paulo, Brazil)
 
0402 D-DIMER LEVEL IS ASSOCIATED WITH THE SEVERITY OF PULMONARY EMBOLISM (PE)
W. Ghanima, M. Abdelnoor, L.O. Holmen, B.E. Nielssen, S. Ross, Dr. F. Wisloff(Řstfold Hospital trust in Fredrikstad, Frdrikstad, Norway)
 
0403 PREFERENCES AND WILLINGNESS-TO-PAY FOR TREATMENT OPTIONS IN PATIENTS ON ORAL ANTICOAGULANT TREATMENT (OAT): A DISCRETE CHOICE EXPERIMERNT
M. Monzini, L.G. Mantovani, M. Carpenedo, M. Moia (University of Milan, Milan, Italy)
 
0404 THE VALUE OF THE DETERMINATION OF ACTIVATED PROTEIN C RESISTANCE (APC-R) IN HEMODIALYSIS PATIENTS
E. Androulakis, G. Tzenakis, H. Kallinou, K. Neonakis, X. Manidaki, G. Stylianou, D. Dialynas, E. Malliaraki, K. Dafnis (Iraklion Univercity Hospital, Iraklion, Greece)
 
0405 ALTERATIONS OF HEMOSTASIS AFTER LAPAROSCOPIC AND OPEN SURGERY
C. Tsiminikakis, A. Skordylaki, F. Samiotaki, C. Oikonomoy, H. Antonioy, C. Bongiorni, F. Marikakis, N. Tsagarakis, T. Diamantis (General Hospital of Hania, Hania, Greece)
 
0406 ROLE OF THE V617F MUTATION OF THE JAK2 IN PATIENTS WITH THROMBOSIS
A.F. Remacha, C. Estivill, M.P. Sarda, J. Mateo, J.C. Souto, C. Canals, I. Tirado, J. Nomdedeu, J. Fontcuberta (Hospital de Sant Pau, Barcelona, Spain)
 
0407 EVALUATION OF NEW COMMERCIAL ELISA KITS IN THE LABORATORY DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME IN VIEW OF THE REVISED CLASSIFICATION CRITERIA OF THE ANTIPHOSPHOLIPID SYNDROME
K. Devreese (Ghent University Hospital, Ghent, Belgium)
 
0408 DIFFERENTIAL EXPRESSION AND REGULATION OF PROTEASEACTIVATED RECEPTORS IN MONOCYTES FROM PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME
P. Buendia, M.J. Cuadrado, M.A. Aguirre, N. Barbarroja, A. Torres, F. Velasco, Ch. Lopez-Pedrera (Hospital "Reina Sofia", Cordoba, Spain)
 
0409 PROCOAGULANT FACTORS IN PATIENTS WITH CANCER
M.S. Molnar, H. Guglielmone, M. Lavarda, M.L. Rizzi, G. Jarchum (Sanatorio Allende, Cordoba, Argentina)
 
0410 THROMBOPHILIC RISK FACTOR OF C46T POLYMORPHISM IN THE FACTOR XII GENE FOR VENOUS THROMBOSIS
M.R. Gutiérrez-Tous, C. Couto, C. Almeida, J.A. Gutiérrez del Manzano, G. Garcia-Donas, I. Simón, A. Fernandez-Palacín, C. Urdanbidelus (University Hospital Valme, Sevilla, Spain)
 
0411 THE DIVERSE IMPACT OF SUBMAXIMAL EXERCISE IN THE FIBRINOLYTIC, COAGULATION AND INFLAMMATORY MECHANISMS IN PATIENTS NEVER TREATED FOR THEIR HYPERTENSION
V. Galea, T. Theodoridis, M. El Ali, H. Triantafyllidi, M. Koutroubi, J. Lekakis, V. Christopoulou-Cokkinou, D. Kremastinos (Evangelismos Hospital, Athens, Greece)
 

BLEEDING DISORDERS

 
0412 COST AND QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS: THE COCHE STUDY
L. Scalone, A. Gringeri, S. Von Mackensen, L.G. Mantovani (University of Milan, Milan, Italy)
 
0413 PROPOSED GUIDELINES FOR ANTICOAGULATION DURING CARDIAC SURGERY USING ARGATROBAN
A. Laber, E. Martin, H. Kloecker (University of Louisville, Louisville, Ky, USA)
 
0414 PILOT STUDY TO ESTABLISH PREFERENCES TOWARDS COAGULATION FACTOR CONCENTRATES USED TO TREAT HAEMOPHILIC PATIENTS WITH INHIBITORS
L. Scalone, A. Gringeri, F. Borghetti, S. Ravera, A. Casati, L.G. Mantovani (University of Milan, Milan, Italy)
 
0415 PRELIMINARY RESULTS FROM THE EUROPEAN ESCHQOL FIELD STUDY
S. von Mackensen, A. Gringeri, K. Berger, P. Giangrande, R. Rolf, L. Mantovani, L. Laszlo, M. Serban, W. Schramm (Institute for Medical Psychology, Hamburg, Germany)
 
0416 INTRACRANIAL HEMORRHAGE IN HEMOPHILIACS RECEIVING NO PROPHYLACTIC REPLACEMENT THERAPY
A.M. Petrescu, M. Serban, W. Schramm (University of Medicine and Pharmacy, Timisoara, Romania)
 
0417 PREVALENCE OF ANTI-HLA AND ANTI-GPIIB/IIIA ALLOIMMUNIZATION IN PATIENTS WITH GLANZMANN THROMBOASTHENIA: EXPERIENCE OF A SINGLE CENTER
C.S. Santoro, A. Rago, A. Antenucci, A. Chistolini, L. Conti, A. De Vellis, L. Di Renzo, L. Laurenti, E. Murgi, M.P. Perrone, M.G. Mazzucconi, (Hematology, Roma, Italy)
 
0418 GENETIC ANALYSIS OF THE COAGULATION FACTOR VIII AND IX GENES IN HUNGARIAN PATIENTS WITH HAEMOPHILIA
A. Bors, H. Andrikovics, A. Szilvási, A. Fehér, A. Marosi, L. Nemes, A. Tordai (National Medical Center, Budapest, Hungary)
 
0419 RELATIONSHIP OF PAI-1 4G/5G POLYMORPHISM AND BLEEDING RISK ASSOCIATED TO CARDIAC SURGERY
J.M. Raya, J.M. Rodriguez-Martin, J.J. Jimenez, J.L. Iribarren, M.J. Rodriguez-Salazar, I. Nassar, P. Machado, P. Reina, A.M. Guijo, M.I. Pérez-Ruiz, L. Hernández-Nieto (Hospital Universitario de Canarias, La Laguna - Tenerife, Spain)
 
0420 FACTOR XI DEFICIENCY AND POST-PARTUM HAEMORRHAGE: BLEEDERS AND NON-BLEEDERS
B. Myers, S.R. Pavord, L. Kean (Queen's Medical Centre, University Hospi, Nottingham, United Kingdom)
 
0421 USE OF LOW DOSE RECOMBINANT ACTIVATED FACTOR VII INFUSION FOR TREATMENT AND PROPHYLAXIS OF BLEEDING EPISODES IN SEVERE FACTOR VII DEFICIENCY
G. Watt, A. Will, P. Bolton-Maggs, P. Mohn, A. Hague, L. Birtwhistle, R. McDermott, S. Pearson, T. Bloodworth, B. Boadman, C.R.M. Hay (Pendlebury Childrens Hospital, Manchester, United Kingdom)
 
0422 EVALUATION OF BONE MINERAL DENSITY IN CHILDREN WITH HEMOPHILIA: MANSOURA UNIVERSITY CHILDREN HOSPITAL (MUCH)EXPERIENCE: MANSOURA, EGYPT
M. Abdelrazik, M.R. Bassiouny, M.A. El-Ziny, H.M. Rabea (Mansoura University Children Hospital, Mansoura, Egypt)
 
0423 CLINICAL AND LABORATORY PECULIARITIES IN CHILDREN WITH VON WILLEBRAND DISEASE
G.T. Tashenova, B.Z.H. Aldaniarova, K.O. Omarova (Scientific Center of Pediatric and Child, Almaty, Kazakhstan)
 
0424 PLATELET FUNCTION TESTING IN URAEMIC PATIENTS
S.J. Ho, T.A. Brighton, R. Gemmell (St George Hospital, Sydney, Australia)
 
0425 ANALYSIS OF CLINICAL AND BIOLOGICAL FACTORS ASSOCIATED TO EXCESSIVE BLEEDING IN CARDIAC SURGERY
J.M. Rodriguez-Martin, J.M. Raya, M.J. Rodriguez-Salazar, J.J. Jimenez, J.L. Iribarren, P. Machado, P. Reina, C. Frias, K. Aminian, I. Nassar (Hospital Universitario de Canarias, La Laguna - Tenerife, Spain)
 
0426 SUBJECTIVE TRAINING EFFECTS ON ADULT PATIENTS WITH HAEMOPHILIA ATTENDING A SPORTS THERAPY PROGRAMME (HEP)
S. von Mackensen, D. Czepa, M. Herbsleb, R. Ziezio, T. Hilberg (University of Hamburg, Hamburg, Germany)
 
0427 THE USE OF FEIBA(R) AND NOVOSEVEN(R) FOR TREATMENT OF BLEEDING EPISODES IN PATIENTS WITH HEMOPHILIA A AND FACTOR VIII INHIBITOR: A SINGLE CENTRE EXPERIENCE
P. Smejkal, J. Muzik, M. Penka, A. Bulikova, M. Matyskova, M. Slechtova, J. Kissova, G. Chlupova, L. Dusek (University Hospital, Brno, Czech Republic)
 
0428 ORTHOPAEDIC STATUS OF PERSONS WITH HAEMOPHILIA IN A DEVELOPING COUNTRY
M. Serban, C. Jinca, L. Pop, D. Poenaru, H. Ionita, A. Lacatusu, M. Bataneant, M. Gafencu, S. Arghirescu, W. Schramm (University of Medicine "V. Babes", Timisoara, Romania)
 
0429 SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND THROMBINACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) ANTIGEN IN CHILDREN WITH DISSEMINATED INTRAVASCULAR COAGULOPATHY
S. Aytac, B. Bayrakci, H. Okur, G. Tekinalp, A. Gurgey (Hacettepe University, Ankara, Turkey)
 

DENDRITIC CELLS AND CELLULAR IMMUNOTHERAPY

 
0430 EXPRESSION AND REGULATION OF ENDOTHELIAL PROTEIN C RECEPTOR IN MONOCYTE-DERIVED DENDRITIC CELLS
E.M. Faioni, L. Tagliavacca, S. Ferrero, U. Gianelli, G. Fontana, S. Bosari, M. Cattaneo (Unitŕ di Ematologia e Trombosi, Milano, Italy)
 
0431 HIGH AFFINITY CYTOTOXIC T CELLS CANNOT OVERCOME THE INTRINSIC RESISTANCE TO THERAPY OF (LEUKEMIC) PRECURSOR CELLS IN DORMANCY
I. Jedema, C.A.M. van Bergen, M.G.D. Kester, R. Willemze, J.H.F. Falkenburg (Leiden University Medical Center, Leiden, The Netherlands)
 
0432 DIFFERENTIATION TOWARDS LEUKEMIC DENDRITIC CELLS IS HINDERED BY THE PRESENCE OF A FLT-3 INTERNAL TANDEM DUPLICATION IN AML BLASTS
I. Houtenbos, M. Westers, J. Ossenkoppele, A. van de Loosdrecht (VU University Medical Center, Amsterdam, The Netherlands)
 
0433 THE NOTCH LIGAND DELTA-LIKE1 PROMOTES THE GENERATION OF INTERSTITIAL AND PLASMACYTOID DENDRITIC CELLS FROM HUMAN MYELOID COMMITTED PROGENITOR CELLS
S. Richter, B. Platzer, L. Heinz, P. Reisner, H. Strobl (Medical University of Vienna, Vienna, Austria)
 
0434 VACCINATION WITH WT1 AND PR3-DERIVED PEPTIDES IN PATIENTS WITH AML/MDS AND MUC1-DERIVED PEPTIDES IN PATIENTS WITH MULTIPLE MYELOMA - PRELIMINARY RESULTS
E.M. Wagner, J. Kuball, M. Wattad, C. Huber, W. Heit, M. Theobald (Johannes Gutenberg University Mainz, Mainz, Germany)
 
0435 CANCER-TESTIS ANTIGENS ARE COMMONLY EXPRESSED IN MULTIPLE MYELOMA AND INDUCE SYSTEMIC IMMUNITY FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
D. Atanackovic, Y. Cao, J. Arfsten, A.R. Zander, C. Bokemeyer, N. Kröger (University Medical Center Hamburg, Hamburg, Germany)
 
0436 PHENOTYPIC CHARACTERIZATION OF PLASMACYTOID DENDRITIC CELLS LINEAGE MATURATION PATHWAY IN NORMAL ADULT BONE MARROW: A FRAME OF REFERENCE FOR UNDERSTANDING DENDRITIC CELL MALIGNANCIES
M.L. Martín, J. Almeida, A. Orfao (Centro de Investigación del Cáncer, Salamanca, Spain)
 
0437 COMBINED TYROSINE KINASE INHIBITION AND IMMUNOTHERAPY AS A STRATEGY TO IMPROVE OUTCOME AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN CHRONIC MYELOID LEUKAEMIA (CML)
C. Craddock, E. Olavarria, M. Griffiths, J.M. Arrazi, S. Siddique, A. Lennard, J. Byrne (Queen Elizabeth Hospital, Birmingham, United Kingdom)
 
0438 CYTOKINE INDUCED KILLER (CIK) CELLS TRANSDUCED WITH ANTI-CD19 CHIMERIC RECEPTORS CONTAINING 4-1BB (CD137) HAVE POWERFUL ANTI-LEUKEMIC ACTIVITY
V. Marin, H. Kakuda, S. Iwamoto, G. D'Amico, D. Campana, A. Biondi (Centro di Ricerca M.Tettamanti, Monza, Italy)
 
0439 INTRACELLULAR EXPRESSION ANGIOTENSIN-CONVERTING ENZYME (ACE, CD143) BY LEUKEMIC DENRITIC CELLS IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS
I.V. Galtseva, V.G. Savchenko, E.N. Parovitchnikova, I.A. Vorobiov, E.M. Gretsov, S.M. Danilov (National Research Center for Hematology, Moscow, Russian Federation)
 
0440 AUTOLOGOUS IMMUNOTHERAPY WITH CYTOKINE INDUCED KILLER CELLS FOR HEMATOPOIETIC AND SOLID TUMORS
P. Olioso, R. Giancola, M. Di Riti, A. Capone, A. Contento, P. Accorsi, D. Natale, F. Angrilli, P. Di Bartolomeo, A. Iacone (Ospedale Spirito Santo, Pescara, Italy)
 
0441 WHOLE CML LYSATE-PULSED DENDRITIC CELLS INDUCE SPECIFIC T CELL RESPONSES TOWARDS CML PROGENITOR CELLS INDICATING THEIR POTENCY FOR APPLICATION IN ACTIVE SPECIFIC IMMUNOTHERAPY
M. Westers, J.J.W.M. Janssen, A.A. van de Loosdrecht, G.J. Ossenkoppele (VU University Medical Center, Amsterdam, The Netherlands)
 
0442 ROLE OF COMMON GAMMA-CHAIN CYTOKINES IN THE MODULATION OF PROLIFERATING CAPACITY AND ON DISTRIBUTION OF T MEMORY AND EFFECTOR CELLS OF EX VIVO GENERATED HUMAN DONOR-DERIVED ANTI-LEUKAEMIA CTL LINES
I. Turin, L. Daudt, R. Maccario, E. Montini, T. Mina, F. Locatelli, D. Montagna (IRCCS Policlinico S. Matteo, Pavia, Italy)
 
0443 IMMUNOGENIC PEPTIDE DERIVED FROM NM23-H2 AS A POTENTIAL TARGET FOR LEUKEMIA-SPECIFIC IMMUNOTHERAPY
S Tschiedel, A. Reinhardt, C. Wölfel, T. Wölfel, H. Rammensee, D. Niederwieser, C. Gentilini (University of Leipzig, Leipzig, Germany)
 
0444 CROSS-COSTIMULATION BY DONOR ANTIGEN PRESENTING CELLS PLAYS A ROLE IN ACUTE XENOGENEIC GRAFT-VERSUS-HOST DISEASE
A. Bondanza, S. Kaneko, M. Ponzoni, F. Ciceri, E. Goulmy, C. Bordignon, C. Bonini (Leiden University Medical Center, Leiden, The Netherlands)
 
0445 DEVELOPMENT AND CHARACTERISATION OF GMP-GRADE CYTOMEGALOVIRUS PP65-SPECIFIC CD8+ AND CD4+ T-CELL LINES FOR ADOPTIVE TRANSFER
M.L. Zandvliet, J.H.F. Falkenburg, I. Jedema, L.M.P. Cox, R. Willemze, H.J. Guchelaar, P. Meij (Leiden University Medical Center, Leiden, The Netherlands)
 
0446 FUNCTIONAL CHARACTERIZATION OF CYTOMEGALOVIRUS (CMV)-SPECIFIC CD4 AND CD8 T CELL LINES GENERATED BY USING PROTEIN-SPANNING POOLS OF PP65 AND IE1 DERIVED PEPTIDES
E. Dander, G. Li Pira, F. Manca, I. Mazzarisi, E. Biagi, A. Biondi, G. D'Amico (Research Center M. Tettamanti, Monza (mi), Italy)
 
0447 MICROBEADS AS ARTIFICIAL APCS AND CELL BRIDGES FOR T CELL CANCER THERAPY
M.A. Sanchez Luengo, M. Villarroel, A. Hernandez, D. Diaz, E. Perucha, H. Barcenilla, C. Burgaleta, J. Garcia-Suarez, H. Bańas, I. Sanroman, B. Pinedo, E. Reyes, J. Jorge, A. Prieto, M. Alvarez-Mon (Universidad de Alcala de Henares, Alcala De Henares, Spain)
 
0448 THE IMMUNOMODULATORY EFFECTS OF HUMAN UNRESTRICTED SOMATIC STEM CELLS ON CORD BLOOD T CELLS
M. Soleimani, A. Atashi, N. Ahmadbeigy, A.A. Movassaghpour (Tarbiat Modarres University, Tehran, Iran)
 

MYELODYSPLASTIC SYNDROMES I

 
0449 VALIDATION OF THE NIJMEGEN PREDICTIVE SCORE FOR INDUCTION THERAPY IN MDS WITH HIGH-RISK MDS OR AML
U. Germing, C. Strupp, S. Knipp, A. Giagounidis, S. Balleisen, B. Hildebrandt, A. Kuendgen, C. Aul, N. Gattermann, R. Haas (University of Düsseldorf, Düsseldorf, Germany)
 
0450 LENALIDOMIDE IN DEL(5Q) MDS PATIENTS: DFFERENT PATTERNS OF RESPONSE
A.A.N. Giagounidis, S. Haase, V. Lohrbacher, M. Heinsch, C. Aul (St. Johannes Hospital, Duisburg, Germany)
 
0451 HIGH INCIDENCE OF THERAPY-RELATED MYELODYSPLASIA AND ACUTE LEUKAEMIA IN PATIENTS TREATED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE FOR INDOLENT LYMPHOPROLIFERATIVE DISORDERS
J. Bowcock, S.M.B. Rassam, Z. Lim, S.M. Ward, M.M. Ryali, G.J. Mufti (Queen Mary's Sidcup NHS Trust, Sidcup, Kent, United Kingdom)
 
0452 IMPAIRED SDF-1-INDUCED MIGRATION OF CD34+ CELLS FROM MDS PATIENTS AS A RESULT OF DECREASED ACTIVATION OF PROTEIN KINASE B, RAC AND FACTIN POLYMERISATION
G.M. Fuhler, A.L. Drayer, P.J. Coffer, E. Vellenga (University Medical Center Groningen, Groningen, The Netherlands)
 
0453 EVI-1 GENE EXPRESSION IN MYELODYSPLASTIC SYNDROMES: QUANTITATIVE ASSESSEMENT AND IN VITRO MODULATION INDUCED BY ARSENIC TRIOXIDE
D. Cilloni, S. Carturan, I. Defilippi, E. Messa, A. Chiarenza, F. Salvi, D. Ferrero, E. Gallo, A. Gallamini, S. D'ardia, F. Marmont, C. Marinone, G. Gaidano, A. Levis, G. Saglio (University of Turin, Turin, Italy)
 
0454 CYTOGENETIC EVOLUTION IN DEL(5Q) MYELODYSPLASTIC SYNDROME
A.A.N. Giagounidis, U. Germing, B. Schlegelberger, B. Hildebrandt, S. Haase, V. Lohrbacher, G. Göhring, L. Wilkens, M. Heinsch, C. Aul (St. Johannes Hospital, Duisburg, Germany)
 
0455 OVEREXPRESSION OF MATRIX METALLOPROTEINASES 2 AND 9 IN MYELODYSPLASTIC SYNDROMES
R. Invernizzi, E. Travaglino, C. Benatti, L. Malcovati, M.G. Della Porta, M. Cazzola (IRCCS Policlinico S. Matteo, Pavia, Italy)
 
0456 A ROLE FOR THE ENDOPLASMIC RETICULUM AND THE MITOCHONDRION IN ERYTHROID CELL APOPTOSIS THAT CHARACTERISES LOW GRADE MYELODYSPLASTIC SYNDROMES
E.G. Emmanuel, J.C.D. Deschemin, C.G. Garrido, C.R. Randriamampita, A.D.K. Dubart-Kupperschmitt, O.B.R. Beyne-Rauzy, F.D. Dreyfus, M.G. Guesnu, C.L. Lacombe, M.P. Mayeux, E.S. Solary, M.F. Fontenay (Inserm U567, Paris, France)
 
0457 ISSUES AFFECTING QUALITY-OF-LIFE IN PATIENTS LIVING WITH MYELODYSPLASTIC SYNDROMES (MDS): RESULTS OF PATIENT FORUM DISCUSSIONS IN EUROPE
K.V. Heptinstall, D. Bowen, P. Fenaux, S. Killick, T. Hamblin, G.J. Mufti (Myelodysplastic Syndromes, Inc., Crosswicks, USA)
 
0458 FOUR DIFFERENT TYPES OF MDS PATIENTS WITH 5Q- ANOMALIES
U. Germing, A. Giagounidis, B. Hildebrandt, A. Kuendgen, N. Gattermann, R. Haas, C. Aul (University of Düsseldorf, Düsseldorf, Germany)
 
0459 THE PROGNOSTIC MEANING OF INVOLVEMENT OF 5QABERRATIONS IN PATIENTS WITH MDS AND COMPLEX KARYOYTPE
U. Germing, A. Giagounidis, B. Hildebrandt, C. Aul, C. Strupp, A. Kuendgen, N. Gattermann, R. Haas (University of Düsseldorf, Düsseldorf, Germany)
 
0460 MRI T2* MEASUREMENTS SHOW NO MYOCARDIAL IRON LOADING IN PATIENTS WITH MYELODYSPLASIA ON LONG-TERM BLOOD TRANSFUSION THERAPY
J. Chacko, D. Pennell, M. Tanner, B. Wonke, T. Levy, T.J. Hamblin, S.B. Killick (Royal Bournemouth Hospital, Bournemouth, United Kingdom)
 
0461 EVIDENCE FOR A ROLE OF CD40 IN THE PATHOGENESIS OF LOW-RISK MYELODYSPLASTIC SYNDROMES
S. Meers, A. Kasran, L. Boon, M. Boogaerts, G. Verhoef, M. Delforge (University Hospital Leuven, Leuven, Belgium)
 
0462 IMMUNOPHENOTYPIC ANALYSIS OF CD34+ CELL SUBSETS IN BONE MARROW SAMPLES FROM MYELODYSPLASTIC SYNDROME PATIENTS
S. Matarraz, M. De Santiago, A. Lopez, C. Salvador, N. Fernandez- Mosteirin, M. Giralt, A. Orfao (University of Salamanca, Salamanca, Spain)
 
0463 FUNCTIONAL TLR-4 IN MDS BONE MARROW CELLS: INVOLVEMENT OF TNFA MEDIATED TLR-4 EXPRESSION IN INCREASED APOPTOSIS
C.I. Maratheftis, H.M. Moutsopoulos, M. Voulgarelis (Medical School, University of Athens, Athens, Greece)
 
0464 ABNORMALITIES OF BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
E. Stavroulaki, M.C. Kastrinaki, A. Damianaki, G. Eliopoulos, H.A. Papadaki (University of Crete School of Medicine, Heraklion, Greece)
 
[ Top of page ]


EHA Executive Office, Westblaak 71, 3012 KE Rotterdam, The Netherlands | Phone: (+31) 10-4361760 | Email:

COPYRIGHT © EUROPEAN HEMATOLOGY ASSOCIATION